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MicroRNA (miRNA) are a class of endogenous non-protein-coding RNA of ~19-
25 nucleotides long that post-transcriptionally regulate protein expression by targeting 
messenger RNAs for cleavage or translational repression. MiRNAs have been implicated 
in the initiation and progression of 160+ human diseases. Unique miRNA differential 
expression signatures can be used as a basis of discriminating against the presence or 
absence of human diseases. MiRNAs are therefore a promising and emerging class of 
disease biomarkers and therapeutic targets; however, the accurate detection of a specific 
miRNA has continued to be a challenging issue. Recently, mass spectrometry (MS) has 
seen remarkable technological advancements making it an attractive alternative to the 
conventional molecular biology miRNA characterization techniques. This study 
consistently documents the development of various analytical techniques aimed at 
characterization of miRNAs. The current literature in the field of miRNA is covered in 
chapter one. In chapter two, two new MS based concepts for detection of miRNA are 
introduced; a) the miRNA is captured using a specific complementary DNA probe, eluted 
and digested with specific endonuclease. The digested miRNA fragments are measured 
by MS resulting in a peak pattern that is dependent on the miRNA sequence i.e. an 
intrinsic mass signature and b) a unique mass signature is created by incorporating extra 
nucleotide(s) to the 3’ end of miRNA and the extended miRNA is measured by using 
MS. The molecular mass of the extended miRNA, which is defined as extended mass 
signature, is expected to be different from the other miRNA within the same sample. 
 
These two approaches can improve the accuracy on qualitative MS identification of 
specific miRNA. To better understand miRNA function however, it is important to 
elucidate the nucleotide sequence of the miRNA. Chapter three of this study introduces a 
novel MS based assay for the sequencing of miRNA through chemical hydrolysis. In this 
study, by taking advantage of the mixing between a miRNA sample and an acidic 
MALDI matrix prior to the MALDI-TOF MS measurements, a unique yet simple and 
relatively cost-effective approach to generate miRNA sequencing ladders was developed. 
By using this method, 100% sequence coverage and accuracy in the sequencing of 
selected miRNAs were achieved. When many samples are involved, the data generated 
from miRNA measurements can be complex and manual data processing is tedious and 
challenging, as such, the spectral interpretation of mass spectrometric data can quickly 
turn out to be the bottleneck in miRNA analysis. The success of MS as a tool for analysis 
of miRNA will therefore strongly depend on the development of relevant computational 
software with the ability to properly interpret and analyze the large data. To meet this 
need, chapter four of this work explains the development of MicroRNA MultiTool, a 
computational software for the rapid interpretation of MS data containing human 
miRNA. Users can directly enter data obtained from mass spectrometric measurement in 
order to obtain the identify of miRNA, highly reducing the time needed to process data. 
The development of such analytical and bioinformatics tools will provide scientists with 
the opportunity to better understand miRNA functions and will be influential in 
propelling the breakthroughs of miRNA in clinical diagnostics and therapeutic fields. 
 
 
 
Schematic abstract depicting analytical assays and bioinformatics solutions developed in 
this study. 
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CHAPTER I 
INTRODUCTION 
1.10 Review of the Literature 
MicroRNA (miRNA) are a class of endogenous non-protein-coding RNA of ~19-
25 nucleotides long that  post-transcriptionally regulate protein expression by targeting 
messenger RNAs for cleavage or translational repression (Iorio et al. 2005). MiRNA 
were discovered in 1993 by Victor Ambros, Rosalind Lee and Rhonda Feinbaum when 
studying the development of the nematode  Caenorhabditis elegans and have since 
revolutionized the understanding of post-transcriptional gene regulation (Omahen 2011). 
The genes that encode miRNA are evolutionarily conserved and are located within exons 
or introns of protein-coding genes or in intergenic areas (Fiorucci et al. 2012). MiRNAs 
have been shown to regulate biological processes that are central to cancer biology such 
as cell growth, angiogenesis, invasion, metastasis (Lee and Dutta 2009), as well as other 
key cellular functions like tissue differentiation, cell proliferation, apoptosis and 
embryonic growth (Lu et al. 2008). It is therefore not surprising that miRNAs are 
implicated in the initiation and progression of more than 160 human diseases including 
numerous cancer types, heart disease and diabetes (Jiang et al. 2009). It has been shown 
that unique miRNA differential expression signatures can be used as a basis of 
discriminating against the presence or absence of human diseases (Calin et al. 2005). 
These properties make miRNAs valuable diagnostic biomarkers (Park et al. 2009), 
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(Ferdin et al. 2010), classification and prognostic tools for human diseases as well as 
potential therapeutic targets (Calin and Croce 2006). 
According to the miRBase database, 2100+ human miRNAs have already been 
reported and the number is constantly increasing (Griffiths-Jones et al. 2006), (Griffiths-
Jones et al. 2008). A single messenger RNA can be targeted by more than one miRNA 
and each miRNA has the ability to regulate several different messenger RNA, this 
immensely increases the ability of miRNAs to regulate gene expression as well as the 
complexity of miRNA analysis (van Rooij and Olson 2007). MiRNAs bind to partially 
complimentary sequences on 3’ untranslated regions (UTR) or open reading frames of 
their target messenger RNA and lead to either translation repression or degradation of the 
messenger RNA (Thomson et al. 2004). Through computational techniques, Friedman et 
al estimated that more than 60% of human messenger RNAs are indeed targets for 
miRNA (Friedman et al. 2009). It is therefore no wonder that miRNA research continues 
to generate increased interest as evidenced by a plot of miRNA discovered and deposited 
in miRBase versus the number or publications reported in SciFinder as shown in Figure 
1.1. 
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Figure 1.1. Number of miRNAs in miRBase versus publications in SciFinder. 
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1.11 MiRNA biogenesis 
The schematic overview of miRNA biogenesis is shown in Figure 1.2. miRNA 
are transcribed by RNA polymerase II or RNA polymerase III as an independent gene or 
as part of a mRNA intron that can range from hundreds to thousands of nucleotides long. 
The transcript is cleaved by a double stranded RNA (ds-RNA) specific ribonuclease 
(RNase) called Drosha in conjunction with a ds-RNA binding protein known as Di-
George syndrome critical region gene (DGCR8) into a hairpin structure of about 70 
nucleotides long called pre-miRNA. The pre-miRNA has a two nucleotide 3’ overhang 
and is exported from the nucleus to the cytoplasm by the nuclear factor exportin-5 with 
the help of a cofactor Ran-GTP. In the cytoplasm, the pre-miRNA is recognized and 
cleaved by a type III RNase endonuclease referred to as Dicer together with its 
corresponding immunodeficiency virus transactivating response ds-RNA binding protein 
(TRBP) into an imperfect miRNA duplex of ~19-25 nucleotides long. Only one of the 
two strands is retained while the other is removed and destroyed. TRBP then recruits a 
human argonaute protein hAgo2 onto the Dicer complex, forming a RNA-induced 
silencing complex (RISC). The Ago2 has two domains; a RNA binding domain and an 
endonucleolytic domain capable of cleaving target mRNA (Wiemer 2007). miRNA are 
thought to regulate gene expression by binding to complimentary sequences on 3’ 
untranslated regions (UTR) or open reading frames (ORF) of target mRNA(Thomson et 
al. 2004). The critical base pairing process occurs through the 5’ seed region (base pairs 
2–8). Perfect or near perfect complementarily of miRNA to target mRNA is thought to 
cause mRNA degradation through RISC endonucleolytic activity while imperfect 
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complementarity stops the translation of miRNA by blocking the ribosome during 
translation (Hutvágner and Zamore 2002). The RISC complex can also effect post-
transcriptional gene silencing by inducing the deadenylation of mRNA through 
mechanisms that are not yet fully understood (Creighton et al. 2009). The origins and 
mechanisms of action of miRNA were thoroughly reviewed by Carthew et al (Carthew 
and Sontheimer 2009). 
 
 
Figure 1.2. Schematic diagram of miRNA biogenesis in a mammalian cell. 
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1.12 MiRNA and diseases 
Recent years have seen a tremendous interests in miRNA analysis especially after 
Calin and co-workers revealed that miRNA play a crucial role in cancer pathogenesis 
either as tumour suppressor genes or oncogenes (Calin et al. 2002), (Backes et al. 2010) 
this is evidenced by the exponential increase in miRNA publications as shown in Figure 
1.1. 
Cancer is a genetic disorder characterized by accumulation of mutations and 
deregulation of gene expression leading to uncontrolled cell proliferation, it has been one 
of the leading causes of death in the United States and around the world; this trend is 
expected to continue as the current population continues to age. The main stages in 
cancer include; initiation, promotion, malignancy, progression and metastasis. The 
regulation of these cellular activities especially gene expression have been the target by 
scientists to elucidate the underlying molecular mechanisms leading to cancer 
development with an aim of providing effective therapies or disease prevention (Negrini 
et al. 2009). Since the discovery of miRNA oncogenic and tumor suppression 
characteristics by Calin et al in 2002, more studies have accumulated evidence that 
deregulation of miRNA expression plays a central role in cancer pathogenesis (Bandrés et 
al. 2006). The expression of miRNAs has been found to vary dramatically across 
different tumor types, these miRNA expression patterns can be used for differentiating 
cancers according to their types and developmental stages. Such strategies can be used 
for prognosis of cancers as well as determination of better treatment choices. Many 
different miRNAs have been identified as diagnostic biomarkers or as possible new 
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therapeutic agents (Park et al. 2009).  The potential for miRNA dependent diagnostics is 
boosted by the ease with which small RNAs can be routinely measured under normal 
hospital laboratories (Meltzer 2005). All research work that focuses on miRNA and/or 
their relationships with cancer do require high specificity and accuracy on measuring 
miRNA. 
Numerous methods for identifying miRNA have been developed and tested. 
Among these methods, the traditional Northern blotting is still being used, which is 
mainly due to its availability in many research laboratories (Várallyay et al. 2008). The 
less labor intensive and more sensitive real-time polymerase chain reaction (PCR)  
method for measuring specific miRNA has been commercialized (Sharbati-Tehrani et al. 
2008). However, due to the small sizes of miRNA, the primer design for PCR has been 
challenging. For achieving higher throughput, microarray technology and the next 
generation sequencing method are available for the analysis of multiple miRNAs 
(Davison et al. 2006), (Motameny et al. 2010), (Lu et al. 2005).  
 
1.13 MiRNA as drugs and therapeutic targets 
With a lot of research having been done on miRNA, it is evident that this class of 
small non-coding RNA can control vital biological processes, current research is 
therefore moving towards translating the information gathered into the development of 
novel therapeutic drugs (Nana-Sinkam and Croce 2011) that exploit the catalytic process 
of natural RNA as a new mechanism of action. Furthermore, miRNA have an added 
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advantage that they can regulate a wide range of oncogenes with high specificity, giving 
miRNA an advantage over cancer drugs that target a single genetic pathway of interest. 
There are currently two major strategies of developing miRNA based treatments, either 
as a) miRNA knockdown through miRNA Antisense Oligonucleotides b) restoration of 
miRNA tumour suppressors through miRNA mimics (Bader et al. 2011).   
 
(a) MiRNA knockdown through miRNA Antisense Oligonucleotides  
Oncogenic miRNAs (oncomirs) are miRNAs that promote proliferation when 
overexpressed in the cell. To counter the presence of oncomirs, miRNA Antisense 
Oligonucleotides can be used. In this case, the therapeutic strategy is to reduce the 
expressed miRNA. This is done through the use of anti-miRNA oligonucleotides. As 
shown on Figure 1.3, the anti-miRNAs consist of short nucleic acids that are 
complementary to the miRNA to be countered. The antisense miRNA bind onto the 
miRNA of interest, preventing them from reaching the target mRNA and thus effectively 
silencing the oncogenic miRNA. This suppresses the effect of the oncomir, and decreases 
disease progression (Feliciano et al. 2011). 
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Figure 1.3. miRNA knockdown through the use of miRNA antisense oligonucleotides. 
  
 
 (b) Restoration of miRNA tumor suppressors through miRNA mimics  
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suitable approaches to alternative miRNA therapies (Maiti et al. 2012). It is important to 
note that miRNA therapies are still in their initial stages and that factors such as cellular 
delivery, suitable biological distribution and general stability will be key to success of 
miRNA therapies (Xu and Anchordoquy 2011). 
  
Figure 1.4. Inhibition of Dicer during miRNA biogenesis by use of small molecules. 
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to the miRNA are hybridized onto the miRNA and the membrane washed to remove non-
specific hybridization before the final measurements are done. The main disadvantage of 
Northern blots is the poor sensitivity of the method especially when measuring 
microRNA with low expression levels. This necessitates the use of large sample sizes, an 
aspect that is trivial especially when sample sources are limited. An improvement to 
conventional Northern blotting that includes use of locked nucleic acids (LNA) on the 
oligonucleotide probes has greatly enhanced the specificity and sensitivity levels of 
Northern blots.  LNAs are bicyclic analogues of nucleotides which exhibit high affinity 
towards their complementary sequences. In LNA, the O2´ and the C4´ atoms are linked 
by a methylene group thereby chemically locking the nucleotide in an N-type (C3’-endo) 
conformation. This results in enhancement of base stacking properties and pre-
organization of the phosphate backbone leading to improved thermal stability of the 
LNAs after they hybridize onto complimentary targets (Várallyay et al. 2007), (Várallyay 
et al. 2008). Nonetheless, Northern blotting is considered a low throughput labor 
intensive method (Sipova et al. 2010),
 
(Qavi et al. 2010). Due to the time and sensitivity 
constraints of Northern blotting, high throughput and more specific methods have been 
adopted for miRNA analysis (Várallyay et al. 2008). 
(b) Microarrays 
A great advantage of using microarrays is the parallel screening of multiple 
miRNAs and comparative miRNA expression analysis on the same platform (Davison et 
al. 2006). Initial steps of miRNA microarray analysis involves extraction of total RNA 
followed by enrichment of the RNA sample for small RNA. Alternatively, small RNA 
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isolation can be done directly from the samples. The miRNA are then labeled. 
Microarrays rely exclusively on the use of nucleic acid probes or their modified formats. 
For example, the use of molecular beacons, locked nucleic acids and peptide nucleic 
acids have already been reported (Hunt et al. 2009). To achieve a specific recognition of 
a known miRNA, the nucleic acid probe whose sequence is complementary to the 
miRNA forms a hybrid with the targeted miRNA through Watson-Crick base pairing. In 
other words, all the existing microarray assays for miRNA analysis rely on the precise 
annealing of miRNA onto complementary nucleic acid probes (Chen et al. 2008; Li and 
Ruan 2009). By carrying out the annealing process between the probe and targeted 
miRNA on a solid surface, e.g. nitrocellulose membrane, or polystyrene microtiter plate, 
any unwanted non-specific binding of the probe can be easily removed by washing the 
surface with a suitable buffer (Cissell et al. 2007). To further improve the specificity as 
well as achieve a high sensitivity for the detection of the miRNA-probe hybrids, various 
reporting labels have been explored. These include both radioactive and non-radioactive 
labels or fluorescent moieties (Chen et al. 2005). The major challenge of designing 
miRNA arrays is the capability to construct probes that can discriminate against many 
highly similar miRNA sequences whose difference can be as few as a single nucleotide. 
Despite their widespread use and acceptance, microarrays lack the ability to identify base 
mismatches between miRNA-probe duplexes which normally leads to non-specific 
hybridization and false signals (Lee et al. 2008). To harmonize the miRNA-probe duplex 
melting temperatures and enhance binding affinity in microarrays, the use LNAs has been 
reported. Regardless of the great progress made in microarray development, results so 
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obtained must be verified using an independent analytical method (Git et al. 2010), (Cho 
2007). Other limitations of microarrays include the requirement for rather large sample 
volumes or alternative sample amplification step as well as the prolonged incubation time 
periods during sample preparation. The labeling of miRNA prior to analysis can be quite 
laborious. These limitations of microarrays contribute towards an increase in analysis 
cost and delay time for obtaining results, factors which have limited microarray 
techniques from point of care applications (Chen and Li 2007). 
 
(c) Quantitative real time polymerase chain reaction 
Quantitative real time polymerase chain reaction (qRT-PCR) is a powerful tool 
for the comparative analysis of miRNA due to its high level of accuracy, sensitivity and 
practical ease as well as its relatively short analysis time when compared to other 
methods. The most commonly used qRT-PCR method for analysis of mature miRNA is 
the stem-loop method which is based on TaqMan assay. The method consists of two main 
steps. In the first step, miRNAs to be analyzed are hybridized onto stem-loop primers 
with the 3’ end of the miRNA next to the 5’ end of the stem loop primer. The miRNA are 
reverse transcribed using reverse transcriptase into copy DNA (cDNA). In the second 
step, a miRNA specific forward primer, a reverse primer and dye labeled TaqMan probes 
are used to quantify the reverse transcribed miRNA product in a conventional TaqMan 
PCR method (Chen et al. 2005). Nevertheless, designing primers for miRNA is 
challenging due to their short sequences which leads to low melting temperatures that 
interfere with the PCR efficiency. Other variations of qRT-PCR such as the invader assay 
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(Allawi et al. 2004) and miR-Q have also been reported (Sharbati-Tehrani et al. 2008). 
Despite its sensitivity, PCR cannot amplify RNA modifications (Bartels and Tsongalis 
2009). 
 
(d) Bead-based technology 
Carboxylated polystyrene microspheres are coupled to miRNA capture probes 
that consist of sequences complementary to those of miRNA to be analyzed. Each 
microsphere is designated specific miRNA and contains a unique combination of two 
fluorescent dyes. The miRNAs are first biotinylated before incubating them with the 
beads. After hybridization, the bead-miRNA complex is isolated though streptavidin 
phycoerythrin-biotin interaction. The complexes are then analyzed by flow cytometry, 
identifying each bead by its color combination. Fluorescence from the phycoerythrin is 
correlated with specific miRNA concentration. Bead arrays, just like microarrays are 
subject to non-specific hybridization and false signals (Bartels and Tsongalis 2009). 
 
(e) Sequencing 
The main advantage of sequencing is that it allows for the discovery of new 
miRNAs. The RNA extracts are first separated using polyacrylamide gel electrophoresis 
(PAGE) and the fraction containing small RNAs is obtained. 3’ and 5’ adapters are 
ligated to the small RNA to create sites for the annealing of primers used for reverse 
transcription of the miRNA. The miRNA are amplified by reverse transcriptase 
polymerase chain reaction (RT-PCR) and the resulting products are cloned into vectors to 
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form a cDNA library (Berezikov et al. 2006). The clones can be sequenced by Sanger 
sequencing method in which 2’-deoxynucleotides and 2’,3’ dideoxynucleotides are used 
in a polymerase dependent synthesis of miRNA cDNA. The cDNA is terminated 
randomly when a dNTP is incorporated into a growing chain. PAGE is used to separate 
the products by size in order to deduce the sequence of the miRNAs. Bioinformatics are 
then used to identify the location of the miRNA in the genome. Next generation 
sequencing technologies are also widely used for the discovery and sequencing of new 
miRNA (Morozova and Marra 2008). Sequencing is however, labor intensive, lengthy 
and cannot provide the information on modified nucleotide in the RNA molecule 
(Durairaj and Limbach 2008).  
Other methods reported for miRNA analysis include rolling circle amplification 
(Jonstrup et al. 2006), and circularization based platforms of miRNA such as miR-ID 
which uses a ligase followed by reverse transcription of the circularized miRNA 
introduced by Kumar et al have also been explored (Kumar et al. 2011). Next generation 
sequencing technologies (Motameny et al. 2010) and bead based techniques that use a 
unique combination of fluorescent dyes have been developed (Lu et al. 2005). RNA 
primed-array based Klenow enzyme (RAKE) method (Nelson et al. 2004) and 
nanotechnology have also been described by Kong et al (Kong et al. 2009). 
1.15 Mass spectrometric sequencing of nucleic acids 
There are two main approaches for the mass spectrometric sequencing of nucleic 
acids 1) the top-down approach and 2) bottom-up approach. In top-down approach, the 
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entire nucleic acid molecule is introduced into the mass spectrometer and ionized. 
Precursor ions of the desired RNA are selected for fragmentation in which cleavage of 
the nucleic acid backbone is induced through gas phase fragmentation. Collision-induced 
dissociation (CID) is the most commonly used fragmentation technique. The 
characteristic spectra obtained from the fragmentation process are then used to piece 
together the nucleic acid sequence (Keough et al. 1993). Other gas-phase fragmentation 
techniques such as electron transfer dissociation (ETD) or electron capture dissociation 
(ECD) have been investigated (Taucher and Breuker 2010). The main advantage of top-
down approach to sequencing is its inherent speed at which data can be generated. 
Fundamentally all structurally conceivable fragmentations of the molecular ion can 
occur, leading to numerous CID fragments. The number of fragment ions increases with 
the increasing length of the precursor ion. Even though the numerous fragmentation 
pathways can increase the confidence of sequence identification, the phenomenon makes 
mass spectra very complex and is therefore a great drawback of the top-down approach 
(Oberacher and Pitterl 2009). A recent attempt by Oberacher et al to sequence of 22 mers 
by the top-down approach yielded the correct sequences in only 90% of cases (Oberacher 
and Pitterl 2011). 
Mass spectrometric sequencing of RNA by the bottom-up approach uses the 
principle of first fragmenting the RNA to create a “mass ladder” whose mass difference 
between adjacent mass spectrometric peaks can be matched to known single nucleotide 
masses in the sequence. The fragments are then measured by a mass spectrometer and the 
information obtained is used to reconstruct the sequence. The most commonly used 
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methods for fragmenting RNA include enzymatic digestion or chemical hydrolysis using 
alkaline or acidic methods. For enzymatic digestion, a combination of 5’ and 3’ 
exonucleases have to be used to degrade RNA from 3’ and 5’ end for a complete mass 
ladder, however, due to variation in enzyme kinetics, multiple MS measurements have to 
be carried out at different stages during the enzymatic process (Hahner et al. 1997a). 
Modifications on RNA such as 2' O-Methyl and phosphothionates make the nucleic acids 
resistant to nucleases digestion and can therefore not be sequenced through enzymatic 
digestion. Enzymatic assays are also time consuming and costly for large-scale 
applications (Schuette et al. 1995). Recently Bahr et al used trifluoroacetic acid to 
hydrolyze and obtain more than 90% sequence of a 22 mer RNA. The phosphodiester 
backbone of the RNA was randomly cleaved through acidic hydrolysis to generate 
fragments that represent a sequencing ladder. Cleavage of the terminal dinucleotides was 
however not observed, and the sequencing was completed by gas phase fragmentation 
using high resolution MS (Bahr et al. 2009). 
 
1.16 Principles of MALDI mass spectrometry 
Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) is a 
mass spectrometric technique that produces protonated gas phase ions and is used for 
obtaining the molecular weights of analytes. MALDI is considered a soft ionization 
technique i.e. allows the analysis of intact molecules with minimal fragmentation and has 
therefore become a common method for the analysis of a wide range of samples 
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including biomolecules such as nucleic acids and proteins. The combination of MALDI 
with time-of-flight (TOF) mass analyzer to form (MALDI-TOF MS) resulted in a simple 
and sensitive and high speed tool for high throughput genomic research (Garcia et al. 
2002). 
In MALDI experiments, the sample is first mixed with a molar excess of a matrix 
and the liquid matrix-sample mixture is spotted onto steel MALDI plate such as that 
shown on Figure 1.5 and air dried. Most MALDI matrices are conjugated weak organic 
acids that exhibit optimal light absorption of the laser used (Aitken 2005). Common 
MALDI-MS lasers are in the ultra violet region with various wavelengths such as the 
frequency-quadrupled Nd:YAG lasers at 266 nm, nitrogen lasers at 337 nm or frequency-
tripled Nd:YAG lasers at 355 nm, however infra-red lasers with a wavelength of ~3 µM 
have also been used (Niu et al. 1998). As shown in figure 1.5 the sample is then irradiated 
using the laser a few nanoseconds at a time. The matrix absorbs the laser light through 
electronic transitions which results in rapid heating, sufficient enough to cause the 
matrix-sample mixture to volatilize into gas phase (Beavis and Chait 1989). The matrix 
serves two main purposes, it absorbs the laser energy to enable desorption, and is acts as 
a source of H
+
 ions that are transferred to the sample for ionization purposes. The ions 
enter a time of flight mass analyzer which measures the time it takes ions of different 
masses to travel from the ion source to the detector. Usually the ions are accelerated 
using an equal potential difference between the ion source and the detector. Since the 
ions are given the same push by the accelerating potential difference, similar ions gain 
similar kinetic energy and the velocity of the ions is therefore determined by the mass to 
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charge ratio (m/z). A schematic diagram of the Applied Biosystems 4700 MALDI-TOF-
TOF –MS instrument used for some of the studies in this work is shown in Figure 1.6.  
Lighter ions travel faster and reach the detector earlier than heavier ions. The time 
taken by an ion of a particular m/z to reach the detector is then converted into a mass and 
plotted against the count/intensity of the ions. However, in some cases, ions of the same 
m/z generated in the ion source and accelerated into the time-of-flight mass analyzer may 
not have exactly the same initial time spread or precisely identical kinetic energies. This 
results in the ions reaching the detector at different times and leads to peak broadening 
and loss of resolution.  
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Figure 1.5. MALDI laser desorption process. 
 
Figure 1.6. Schematic diagram of ABI 4700 MALDI TOF Mass Spectrometer. 
Several solutions such as reflectrons have been developed to compensate for these 
differences. The reflectron is an optic ion "mirror" at the end of the time of flight tube 
consisting of a series of plates with increasing electric field that reverses the ions flight 
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path back in the direction of the flight tube. Ions of the same m/z with slightly different 
kinetic energies penetrate the reflectron to different depths, with the higher kinetic energy 
ions arriving at the reflectron first and penetrating deeper than ions will lesser kinetic 
energy. The increased flight path of the high kinetic energy ions allows ions of the same 
m/z and different initial kinetic energies to travel and reach the detector at the same time, 
effectively increasing mass resolution (Aitken 2005).  
The development of new easy-to-use methods for the characterization of miRNA 
will play an important role in understand gene regulation by miRNA in both diseased and 
normal conditions. The subsequent chapters describe the development of various tools for 
the identification and characterization of miRNA. 
1.20 Purpose of Study 
The purpose of this study was to develop highly specific and selective assays for 
the characterization of miRNA as well as designing bioinformatics solutions that assist in 
the interpretation of data from mass spectrometric measurements of miRNA. 
1.30 Hypothesis and Specific Aims  
Hypothesis 1 
Specific miRNA can be captured by using a complementary DNA probe. The 
miRNA can then be eluted and digested with specific endonuclease. The digested 
miRNA fragments are directly measured by using MS giving rise to an intrinsic miRNA 
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signature, alternatively, a unique extended mass signature can be created by incorporating 
one or more than one extra nucleotides to the 3’ end of miRNA and the extended miRNA 
measured by using MS. The two different approaches to create a unique mass signature 
which can improve the accuracy on qualitative MS detection of specific miRNA. 
 
Specific aim 1  
To design a highly specific assays for the intrinsic and extended mass 
spectrometric signatures for detecting miRNA. 
 
Hypothesis 2 
By taking advantage of the mixing between a miRNA sample and MALDI matrix 
prior to the MALDI-TOF MS measurements and the acidity of MALDI matrix, a unique 
yet simple and relatively cost-effective approach to generate miRNA sequencing ladders 
can be developed. 
 
Specific aim 2 
To utilize acidic MALDI matrix to hydrolyze the phosphodiester bonds in each 
miRNA molecule, to produce sequencing ladders of the miRNA molecule prior to 
MALDI-TOF MS measurements, followed by elucidation of the miRNA sequence. 
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Hypothesis 3 
The constantly increasing number of human miRNA and the recent discoveries of 
miRNA containing modified nucleotides has continued to make miRNA mass 
spectrometric data analysis a great challenge, however, the development of relevant 
computational software can enable the direct identification of miRNA from MS data 
facilitating the rapid interpretation of MS data containing modified or unmodified human 
miRNA. 
 
Specific aim 3 
To build a software that contains databases of all known human miRNA 
sequences as well as RNA modifications where users can directly enter data obtained 
from MS measurement in order to obtain the identify of both modified or unmodified 
miRNA. 
 
1.40 Significance of the Study 
According to recent studies in mir2disease website (http://www.mir2disease. 
org/), a publicly accessible database linking different miRNAs to their corresponding 
related diseases, miRNAs are implicated in the initiation and progression of more than 
160 human diseases, including different cancer types, heart diseases and diabetes (Jiang 
et al. 2009) and have been shown to regulate biological processes that are central to 
cancer biology. The regulation of these processes especially gene expression have been 
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the target by scientists to elucidate the underlying molecular mechanisms leading to 
cancer development with an aim of providing effective therapies or disease prevention 
(Negrini et al. 2009). Since the discovery of miRNA oncogenic and tumor suppression 
characteristics by Calin et al in 2002, more studies have accumulated evidence that 
deregulation of miRNA expression plays a central role in cancer pathogenesis (Bandrés et 
al. 2006). The expression of miRNAs has been found to vary dramatically across 
different tumor types, these miRNA expression patterns can be used for differentiating 
cancers according to their types and developmental stages. Such strategies can be used 
for prognosis of cancers as well as determination of better treatment choices. Many 
different miRNAs have been identified as diagnostic biomarkers as well as in the 
development of new therapeutic treatments (Park et al. 2009). The assays and 
bioinformatics tools developed in this work serve to fill the void in the increased demand 
for the development of more efficient, accurate and rapid methods for identification, 
sequencing or sequence verification of miRNAs. 
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CHAPTER II 
CREATING MASS SIGNATURES FOR THE DETECTION OF microRNA
      
 
    Parts of the work presented in chapter II has been published in the Royal Society   
of Chemistry Analytical Methods Journal and is referenced as Wambua DM, 
Tannous BA, Chiu NHL. Creating Mass Signatures for the Detection of 
MicroRNA. Anal. Methods, 2012, 4 (10), 3453 – 3459. 
 
 
2.10 Introduction 
MicroRNA is a class of endogenous non-coding RNA which has ~19-25 
nucleotides (nt). Currently, there are more than 2,100 human miRNA reported in the 
literature (Griffiths-Jones et al. 2006), (Griffiths-Jones et al. 2008). With the formation of 
RNA-induced silencing complex (RISC), specific miRNA can recognize and bind to its 
corresponding messenger RNAs (mRNA). The miRNA binding can lead to either the 
degradation of mRNA or the translation of mRNA being blocked (Wiemer 2007). Owing 
to these regulatory functions of miRNA on protein expression, miRNAs have been used 
as biomarkers for differentiating cellular activities, especially the activities that are 
related to diseases (Iorio et al. 2005), (Jiang et al. 2009), (Calin et al. 2005), (Park et al. 
2009), (Ferdin et al. 2010), (Calin and Croce 2006), (Calin et al. 2002), (Backes et al. 
2010). More recently, miRNAs have also been used as drugs, for example, the restoration 
of miR-26 levels with miRNA mimics has been proposed in a scheme for the treatment of 
liver cancer. Numerous methods for identifying miRNA have been developed and tested. 
Among these methods, the traditional Northern blotting is still being used, which is 
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mainly due to its availability in many research laboratories (Várallyay et al. 2008). The 
less labor intensive and more sensitive real-time polymerase chain reaction (PCR) 
method for measuring specific miRNA has been commercialized (Sharbati-Tehrani et al. 
2008). However, due to the small sizes of miRNA, the primer design for PCR has been 
challenging. For achieving higher throughput, microarray technology and the next 
generation sequencing method are available for the analysis of multiple miRNAs 
(Davison et al. 2006), (Motameny et al. 2010), (Lu et al. 2005). Similar to other high 
throughput analysis, the challenges of using either method are the needs for suitable 
bioinformatics software to analyze the experimental data as well as the relative high costs 
on purchasing the equipment and consumable reagents. All the above methods rely on 
using a reporting molecule that has been attached to a nucleic acid probe or primer to 
generate a detection signal. In other words, the end-point signal was not directly obtained 
from miRNA. Theoretically, the direct measurement of miRNA can provide higher 
accuracy than measuring the reporting molecule. With the development of soft ionization 
techniques in mass spectrometry (MS), for example matrix-assisted laser 
desorption/ionization (MALDI), it has become practical to measure the molecular mass 
of various biomolecules (Bahr et al. 2009).  Besides achieving high accuracy on the 
detection of specific miRNA, the direct MS measurement of miRNA can also be used to 
discover or detect miRNA modifications, such as nucleotide addition or deletion, 
conversion of adenosine to inosine, and methylation (Nishikura 2010). 
In this report, we introduce a new concept that can further enhance the accuracy 
on using the direct MS measurements of miRNA. The concept aims at creating a unique 
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signature in the mass spectrum of miRNA. To achieve this goal, one way is to digest a 
specific miRNA with an endonuclease prior to the MS measurement. Before the RNase 
digestion, miRNA was first isolated from a sample by using a complementary DNA 
probe. The captured miRNA was eluted from the probe and digested with RNase. All 
digested RNA fragments were then measured by using MS. The result was the creation of 
a unique pattern of peaks that corresponds to the digested miRNA fragments in the mass 
spectrum. By using this experimental approach i.e. capture and digest the miRNA of 
interest, the unique pattern of peaks is defined as a mass signature in this study (Figure 
2.1a). Alternatively, a unique mass signature can be created by using the template-
dependent activity of DNA polymerase to extend the 3’ end of miRNA with a specific 
type and number of nucleotides (Figure 2.1b). In this way, the extended miRNA has a 
unique molecular mass which is different from the molecular masses of other miRNA 
within the same sample.  
2.20 Materials and Methods 
Two synthetic RNA oligos with the same sequence as the human  
miR-153 (5’ p-UUGCAUAGUCACAAAAGUGAUC-OH 3’), and  
miR-183-5p (5’ p-UAUGGCACUGGUAGAAUUCACU-OH 3’) were synthesized and 
HPLC purified by Integrated DNA Technologies (San Diego, CA, USA). Oligo dT 
coated magnetic beads and binding buffer (20 mM Tris-HCl, 500 mM LiCl, 0.5% LiDS, 
1 mM EDTA, 5 mM DTT at pH 7.5), 2’-deoxynucleoside-5’-triphosphates (dATP, dTTP, 
dGTP, and dCTP) and Klenow Fragment (3´→5´ exo-) of DNA Polymerase I (5000 
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units/mL) together with the hybridization buffer (10 mM Tris-HCl, 50 mM NaCl, 10 mM 
MgCl2, 1 mM Dithiothreitol, pH 7.9 at 25°C) were all purchased from New England 
BioLabs (Ipswich, MA, USA). 2’,3’-dideoxynucleoside triphosphate set (ddATP, ddTTP, 
ddGTP and ddCTP) and  RNase T1 from Aspergillus oryzae were bought from Roche 
(Indianapolis, IN, USA). Ammonium citrate dibasic, triethylammonium acetate buffer 
(TEAA) and 3-hydroxypicolinic acid (3-HPA), 2’,3’,4’ trihydroxyacetophenone (THAP) 
were acquired from Sigma Aldrich (St. Louis, MO, USA). Acetonitrile and methanol, 
both were HPLC grade, were obtained from Fisher Scientific (Pittsburgh, PA, USA). 
Non-sterile 0.22 µm low protein binding Durapore (PVDF) syringe driven membrane 
filter units (25mm) were purchased from Millipore Corp. (Bedford, MA, USA). 
Deionized water obtained from a Barnstead NANOpure Diamond Water Purification 
System (Dubuque, Iowa, USA) was used for reconstitution and dilution of all oligos. 
2.21 Design of DNA capture probes 
In order to separate a specific miRNA from a sample, a DNA oligo was used as a 
probe to capture the miRNA. The design of the DNA probe can be divided into three 
parts: (1) the complementary DNA sequence for capturing miRNA is strategically placed 
in the middle of the probe, (2) the downstream sequence of each DNA probe has a 
poly(dA)20 tail, and (3) the upstream sequence has a variable sequence of 15 nucleotides. 
The two DNA probes that were used to capture the selected miRNAs in this study are 
shown on Figure 2.2. The underlined section is the complementary sequence for 
capturing corresponding miRNA. Both DNA probes with hydroxyl groups at both 5’ and 
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3’ ends were ordered from Integrated DNA Technologies (San Diego, CA). The 
Integrated DNA Technologies OligoAnalyzer software was used to evaluate the cross 
hybridization of DNA probes with other possible miRNA, and ruled out the formation of 
hairpins or substantial secondary structures of DNA probes that would otherwise interfere 
with the hybridization.  
 
 
Figure 2.1. Schematic diagram of (a) intrinsic and (b) extended mass signatures 
The two synthetic miRNAs (miR-153 and miR-183) and their respective DNA 
capture probes (miR-153 DNA probe and miR-183 DNA probe) used in this study are 
shown in Figure 2.2. The sequences underlined on the DNA capture probes are 
complementary to the specific miRNAs. 
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2.2 (a)  
                       
                       5' pUAUGGCACUGGUAGAAUUCACU-OH (miR-153) 
                           |||||||||||||||||||||| 
 3' HO-AAAAAAAAAAAAAAAAAAAAATACCGTGACCATCTTAAGTGAGATCACAATAGGCGA-OH 
(Probe) 
 
 
 
2.2 (b) 
 
                       5' pUUGCAUAGUCACAAAAGUGAUC-OH (miR-183) 
                           |||||||||||||||||||||| 
 3' HO-AAAAAAAAAAAAAAAAAAAAAACGTATCAGTGTTTTCACTAGCTAGACAATAGGCGA-OH 
 
 
Figure 2.2. (a) miR-183 and (b) miR-183 hybridized onto DNA capture probes. 
 
 
Table 2.1. Molecular masses of miR-153, miR-183 and their DNA capture probes. 
Oligo    Neutral Mass (Da) Positively charged Mass (Da) 
hsa-miR-153 7090.272 7091.280 
hsa-miR-183 7083.232 7084.240 
miR-153  DNA probe 17660.699 17661.707 
miR-183 DNA probe 17654.700 17655.708 
 
 
2.22 Intrinsic mass signature by digestion of miRNA 
20 pmol of miRNA was mixed with 30 pmol of complementary DNA capture 
probe in a hybridization buffer (10 mM Tris-HCl, 50 mM NaCl, 10 mM MgCl2, 1 mM 
Dithiothreitol, pH 7.9). The total reaction volume was 15 µL. The reaction mixture was 
heated to 95 °C for 5 min to denature the miRNA and DNA capture probe. This was 
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followed by cooling the reaction mixture to 37 °C at 2.0
0
C/min, during which the miRNA 
annealed to the DNA capture probe. The miRNA-DNA probe duplex was then 
immobilized on the surface of oligo dT coated magnetic beads (60 µL) through the 
interactions between the poly(dA)20 tail on the DNA probe and the oligo dT. Before using 
the beads, they were washed in 100 µL of binding buffer which was supplied with the 
beads. The beads were resuspended in 100 µL of binding buffer, and added to the 
solution that contained the miRNA-DNA probe duplex. The mixture was incubated at 
room temperature for 10 minutes with occasional mixing. The beads were washed twice, 
each time with 100 µL of 200 mM TEAA buffer at pH 7.0. After that, miRNA was eluted 
from the beads by adding 5 µL of deionized water to the beads, and the mixture was 
heated up to 50 °C for 2 minutes. The eluted miRNA was digested with 5 U of RNase T1 
at 37 °C for 10 minutes (Douthwaite and Kirpekar 2007). The digested RNA fragments 
were measured by using MALDI-TOF MS as described later in this section. 
2.23 Extended mass signature by miRNA-primed extension 
The use of DNA capture probe to capture the corresponding miRNA was carried 
out by the same protocol as described above. After the annealing of miRNA to the DNA 
capture probe, the 3’ end of miRNA was enzymatically extended by adding 10 µL of a 
reaction cocktail that contained a suitable 2’,3’-dideoxyribo-nucleotide triphosphate 
(ddNTP) or mixture of suitable 2’-deoxyribo-nucleotide triphosphate (dNTP) and 2’,3’-
dideoxy- ribonucleotide triphosphate and 6.75 U of Klenow Fragment (3´→5´ exo
-
) in 
the hybridization buffer. The final concentration of each nucleotide triphosphate in the 
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reaction mixture was 33 µM. The mixture was incubated at 37 °C for 20 minutes or 40 
minutes to perform single or double nucleotide extension of miRNA, respectively. 
Following the 3’ extension, the miRNA-DNA probe duplex was immobilized on the 
magnetic beads as described above. After washing the beads, the extended miRNA was 
eluted in 5 µL of deionized water with heating at 50 °C for 2 minutes. The extended 
miRNA was measured by using MALDI-TOF MS as described later in this section. For 
experiments that involved the analysis of two miRNAs, the amount of dNTP or ddNTP, 
Klenow fragment, magnetic beads, hybridization and washing buffers was doubled. 
2.24 Preparation of MALDI-TOF MS samples 
3-HPA was selected as the MALDI matrix unless stated otherwise. The 3-HPA 
solution was prepared by dissolving 35.0 mg of 3-HPA and 8.80 mg of ammonium citrate 
dibasic in 1.0 mL of 10 % acetonitrile as described by Chiu et al (Chiu 2009). To dissolve 
the matrix, the solution was vortexed for 1-2 minutes. Before using the matrix solution, it 
was filtered through a membrane filter and stored at −20 °C for not more than one month. 
The stainless steel MALDI sample plate was cleaned with water and methanol before use. 
All MALDI samples were prepared by the thin-layer method. Specifically, 0.3 µL of 
MALDI matrix solution was spotted on the sample plate and was completely air dried 
before spotting 0.3 µL of the sample on top of the dried matrix. 
2.25 MALDI-TOF MS measurements 
A MALDI-TOF mass spectrometer (4700 Proteomics Analyzer, Applied 
Biosystems, Framingham, MA) was used for all MS measurements. Each sample was 
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measured by using the linear high mass positive mode in the 4000 Series Explorer 
Version 3.0 software, unless stated otherwise. The Nd:YAG laser (200 Hz) was set at 
5,000 arbitrary units with maximum setting at 7,900 arbitrary units. The focus mass was 
the expected mass of undigested or extended miRNA in each sample. Molecular ions 
were extracted from the ion source after 450 ns of delayed time. The accelerating voltage 
was +20.0 kV and grid voltage was +18.8 kV. The instrument was equipped with a 200 
Hz digitizer. The sampling bin size was 0.5 ns with an input bandwidth of 500 MHz, and 
a vertical full scale was 500 mV. The linear detector voltage was +2.0 kV. The pressure 
inside the entire instrument was maintained at the level of 10
−8
 Torr. Each spectrum was 
automatically acquired by accumulating the results of 3,000 shots with random edge-
biased positioning of each laser shot. By using the Data Explorer Version 4.6 software, 
resulting mass spectra were calibrated. 
2.26 Optimization MS measurements and enzymatic extensions 
Since the introduction of MALDI-MS in 1985, a great deal of effort has been 
directed towards understanding the mechanisms underlying the process of desorption and 
ionization. Although these processes are still not fully understood, several key parameters 
that affect the quality of results obtained such as matrix conditions, laser intensity, 
number of laser shots and delays in ion extraction have been well documented (Guenther 
et al. 2010).  Sample preparation techniques have been shown to greatly influence the 
quality of mass spectra obtained in MALDI MS measurements. Factors that affect signal 
intensity include matrix solvent composition, matrix-sample ratios, pH and the rate or 
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nature in which the matrix- sample- cocrystals are grown (Cohen and Chait 1996).  Our 
group and others have previously demonstrated that 3-HPA and THAP are the most 
suitable MALDI matrices for the analysis of nucleic acids. Of the two matrices, 3-HPA is 
best suited for the measurement of RNA of high molecular weight while THAP is best 
used for RNA of low molecular weight (Chiu 2009), (Kirpekar et al. 2000). The MALDI 
measurements were performed using 3-HPA as the MALDI matrix except for the analysis 
of RNase digested miRNA in which case THAP matrix was used. To optimize the mass 
spectrometric measurements of miRNA, the factors that affect the signal of measured 
RNA were considered.  In all circumstances, the samples consisted of 0.3 µL of miR-183 
and were prepared through the thin layer method using 3-HPA matrix as explained under 
materials and methods. The samples were then analysed using Applied Biosystems 4700 
MALDI-TOF MS in the positive ion mode. 
 
(a) Optimization of MALDI matrix volume, laser intensity, number of laser shots and 
delay time 
miR-183 was separately analysed by MALDI-MS using varying volumes of 3-
HPA matrix. As shown in Figure 2.3 (a) the signal/noise ratio (S/N) or the measured 
miR-183 increased with increasing matrix volume. The highest S/N was observed when 
0.3 µL of matrix was used. The S/N slightly reduced with increased matrix volume. Laser 
intensity was varied from 3000 to 7000 arbitrary units (arb); the highest setting of the 
laser is 7900 arb. As shown in Figure 2.3 (b), the highest S/N was observed with laser 
intensity of 5000 arb, after which a steady drop in S/N was observed. This is in 
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agreement with previous studies that have shown that minimum laser intensity is required 
to observe the analyte ions, thereafter, the S/N increases as a function of the increasing 
laser intensity until such a time that the laser intensity starts to cause fragmentation of the 
analyte (Guenther et al. 2010). The laser energy was held constant at 5000 arb and the 
number of laser shots used were varied from 500-4000 shots with 500 shot increments. 
As shown in Figure 2.3 (c) the highest signal was achieved with 3000 laser shots (Holle 
et al. 2006). 
The main cause of mass resolution loss in linear MALDI TOF-MS is attributed to 
the difference in flight times of ions with identical mass to charge ratios caused by their 
different initial velocities. This is because this initial velocity component of the ions also 
contributes to the final velocity that is attained by ions of a particular m/z during their 
acceleration out of the ion source and into the field free flight tube. There are two main 
ways of extracting ions; continuous and delayed. For continuous mode the ions are 
extracted and accelerated towards the detector immediately after their formation, under 
these conditions, no flight time compensation is made for ions with the same m/z but 
different initial ion velocities. This leads to ions of same m/z reaching the detector at 
different times, resulting in wide peaks and a great loss of resolution. In delayed ion 
extraction, the extraction of ions is discontinuous. A time delay is employed between the 
formation of ions and their extraction from the source. During this delay time, the ions 
shift to new positions depending on their velocities. This delay time allows the high 
density plume to expand thereby reducing collisional kinetic energy. The resulting 
change in position and potential energy has been shown to compensate for the differences 
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in initial ion velocity. When potential energy is applied to accelerate the ions towards the 
detector, ions of the same m/z travel together leading to narrower peaks and better 
resolution compared to the continuous ion extraction (Juhasz et al. 1996). 
In these experiments, the delay time was varied from 200-800 ns and plotted 
against the resolution of the resulting spectra as shown in Figure 2.3 (d). The highest 
resolution was observed at 400 ns beyond which the resolution reduced sharply. The 
drastic reduction in resolution with increasing delay time could be due to the loss of ions 
during the extended period of time that the ions spend in the ion source before extraction.  
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Figure 2.3. Optimization of MALDI matrix volume, laser intensity, number of laser shots 
and delay time  
 
 
The results in Figure 2.3 were obtained by analysis of miR-183 and show (a) a 
graph of volume of 3 HPA matrix vs signal to noise ratio (b) laser intensity vs signal to 
noise ratio, (c) number of laser shots vs signal to noise ratio and (d) delay time vs peak 
resolution. The spectra were obtained using thin layer sample preparation technique in 
positive ion mode.  
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(b) Optimization of Enzymatic Extension 
 
The Klenow Fragment (3´→5´ exo-) used in these studies can incorporate non-
natural and modified nucleotides such as dideoxynucleotides or chemically modified 
nucleotides in a template depended manner, as long as the nucleotides are good substrates 
(Verma and Eckstein 1998). The Klenow Fragment used in these studies is a 
proteolytically cleaved product of E. coli DNA Polymerase I which retains its polymerase 
activity, but has lost its 5'→3' exonuclease activity (Klenow and Henningsen 1970). A 
mutation performed on D355A and E357A also abolishes the 3´→5´ exonuclease 
activity. The exonuclease inactivity of the Klenow Fragment polymerase used in this 
study was important in order to ensure that modified nucleotides used for miRNA 
extensions were not excised. The time required to complete substrate incorporation does 
vary considerably. Several groups that have done similar enzymatic incorporation have 
reported variable durations required to complete the enzymatic extension depending on 
the modified nucleotide being incorporated (Munafó and Robb 2010), (Lieu et al. 2005). 
It was therefore necessary to find optimal time for the enzymatic reaction. The reaction 
mixture was incubated as outlined in materials for different durations of time and 
analyzed for the extended miRNA. The results for single nucleotide incorporation are 
shown in Figure 2.4. 2.4 (a) shows miR-183 before extension 2.9 (b) shows the analysis 
of the miRNA after a 10 minute incubation period having extended miR-183 and residual 
unextended miR-183. It was therefore necessary to increase the incubation time in order 
to achieve a complete extension of the miRNA. Figure 2.4(c) shows the results obtained 
after a 20 minute incubation period. There was no residual unextended miR-153 observed 
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and therefore subsequent single nucleotide extension experiments were carried out by 
incubating the reaction mixture for 20 minutes. The double nucleotide enzymatic 
extension of miR-183 was optimized using a similar approach as the single nucleotide 
extension. Figure 2.5(a) and (b) shows the results of 10 and 20 minute reactions. After 10 
minutes incubation, the reaction contained a mixture of unextended miR-183 and singly 
extended miR-183, further incubating the mixture for 20 minutes (2-5b) yielded a 
mixture of singly and doubly extended miR-183 with no peaks identified from 
unextended miR-183. Performing the reaction for a duration of 40 minutes enabled 
completion of the reaction as shown in Figure 2.5(c).  
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Figure 2.4. Optimization of time for single nucleotide extension of miR-183 using dCTP 
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Figure 2.5. Optimization of time for double nucleotide extension of miR-183 using dCTP 
and ddTTP. 
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2.30 Results and Discussion 
Recently, the use of MALDI-TOF MS to directly measure RNA has been reported 
by Limbach and his co-workers (Hossain and Limbach 2009), (Banoub et al. 2010). With 
the direct miRNA measurements, the MS approach is theoretically more accurate than 
those methods using a detection signal generated from a reporting label to determine the 
presence of a specific miRNA. However, before carrying out the MS measurements, 
specific miRNA ought to be separated from its aqueous sample, especially when cellular 
materials are involved. As demonstrated in a wide variety of molecular biology 
techniques, one of the most effective ways to isolate a specific miRNA with known RNA 
sequence is by using a complementary DNA probe to capture the miRNA target. 
However, with > 2,100 different human miRNA, plus other types of small RNA that may 
co-exist in the same biological sample, non-specific RNA hybridization to the DNA 
capture probe is unavoidable. This is further complicated by the fact that there are 
isobaric miRNA i.e. miRNA with different RNA sequences but identical molecular 
masses. For example, human miR-183-5p and six other human miRNA share the exact 
same molecular mass of 7083.13 Da. Thus, even with the use of high resolution mass 
spectrometry, the molecular ions of isobaric miRNA cannot be resolved. To address these 
issues and to ensure higher accuracy is achieved when MS is used to measure miRNA, 
we have developed a new concept which aims to create a unique signature in the mass 
spectrum of miRNA. To achieve this goal, one way is to digest a specific miRNA with a 
specific endonuclease prior to the MS measurement (Figure 2.1 a). Before the RNase 
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digestion, miRNA was first isolated from a sample by using a complementary DNA 
probe. The miRNA-DNA probe duplex was then immobilized on oligo dT coated 
magnetic beads and washed. The desalted miRNA was subsequently eluted from the 
probe and digested with RNase. For the proof of concept, human miR-183 which is up-
regulated in glioblastoma was selected as a model in this study, and RNase T1 that 
cleaves the phosphate backbone at the 3’ end of every guanosine was used to digest the 
selected miRNA. The digested miRNA fragments were then ready to be measured by 
using MS. Among various MS techniques, MALDI-TOF MS was chosen in this study 
because of its small sample size (0.3 µL), relative large mass range of up to 1.5 MDa, 
high sample throughput (~1 sec/sample), automatable data acquisition and the possibility 
to archive the same MALDI samples that have been measured.  
Based on the mechanism for RNase T1 digestion shown in Figure 2.6, the 
cleavage of a phosphodiester bond on the RNA phosphate backbone would first give rise 
to a 2’,3’-cyclic phosphate on each 5’ digested fragment. The 2’,3’-cyclic phosphate is 
considered to be the molecular structure of an intermediate. Following the ring opening 
of 2’,3’-cyclic phosphate, each 5’ digested fragment would have a linear 2’ phosphate 
group at its 3’ end (Douthwaite and Kirpekar 2007). The results that were obtained from 
the analysis of a sample that contained miR-183 are shown in Figure 2.7. To minimize 
the interference from the molecular ions of MALDI matrix and its clusters, the low mass 
cut-off in the data acquisition was set at 950 m/z. For this reason, the molecular ions of 
digested guanosine 3’ monophosphate were not detected. As indicated in Figure 2.7, all 
other RNA fragments resulting from the digestion of miR-183 were identified. These 
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results exemplify the approach of using a DNA probe to capture a miRNA of interest and 
the subsequent digestion of miRNA with a specific RNase can be used to create a pattern 
of peaks which is unique to the miRNA being analyzed. Thus, the unique pattern of peaks 
is a mass signature that can be used to identify the miRNA. In this study, a unique pattern 
of peaks that correspond to the digested miRNA fragments is defined as an intrinsic mass 
signature as described in Figure 2.1 (a). This is because the pattern of peaks is dependent 
on the intrinsic property, i.e. RNA sequence, of a specific miRNA. In comparison to the 
use of a single peak which corresponds to an undigested miRNA to identify a specific 
miRNA, the concept of using an intrinsic mass signature, i.e. multiple peaks, is more 
accurate and robust. Following the isolation of miRNA, other specific endonuclease, like 
RNase A, can also be used to digest miRNA and create a unique intrinsic mass signature.  
The digested RNA fragments that contained either 2’,3’-cyclic phosphate or 3’ 
phosphate were detected with an expected mass difference of 18 Da. To induce the ring 
opening, the incubation step of RNase T1 digestion was extended from 10 min to 20 min, 
but the two peaks that corresponded to the 2’,3’-cyclic phosphate group remained 
detectable in repeated experiments. From the viewpoint of analyzing the spectral data, the 
presence of the peaks that correspond to 2’,3’-cyclic phosphate group  reinforce the 
identity of the peaks that correspond to the linear 2’ phosphate group. Thus, in the case of 
the selected miR-183, the intrinsic mass signature would include all six peaks as shown 
in Figure 2.7. 
To demonstrate the feasibility of the concept of creating a unique mass signature 
to accurately identify a specific miRNA, the miRNA-DNA probe dulplex was 
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immobilized on the surface of magnetic beads by using the simple and well established 
approach of specific molecular interactions between the poly(dA) tail on the DNA probe 
and oligo dT on the magnetic beads. It is important to note that other approaches for 
immobilizing the miRNA-DNA probe duplex can also be used, such as the 
immobilization of biotinylated DNA probe on streptavidin-coated magnetic beads.  
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Figure 2.6. Mechanism of RNase hydrolysis. 
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Table 2.2. Expected RNase T1 digestion fragments of miR-183 
Cleavage 
position 
Linear phosphate (Da) 2’ 3’ cyclic phosphate Da) Sequence 
 U1:G4  1383.743   1365.728  pUAUGp 
G5:G5    362.216   344.201 Gp 
C6:G10   1607.962   1589.947  CACUGp 
G11:G11    362.216  344.201 Gp 
U12:G14    997.594   979.579  UAGp 
A15:U22   2453.529  - AAUUCACU 
Unxtended miR-183 UAU GGC ACU GGU AGA AUU CAC U ([M-H]
-
- =  7082.225) 
These expected theoretical molecular masses of RNase T1 digestion from unextended 
miR-183 in negative ion mode MS were calculated using Mongo Oligo Mass Calculator 
version 2. 
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Figure 2.7. MALDI-TOF mass spectrum of miR-183 after RNase T1 digestion 
The peak labels without asterisks (*) represent the digested fragment that contains 
a linear 2’ phosphate group, and the peak labels with asterisks represent the digested 
fragment that contains a 2’,3’-cyclic phosphate group. The spectrum was obtained with 
THAP matrix and linear negative ion mode. The THAP matrix solution was prepared by 
dissolving 20.0 mg of 2’,3’,4’ THAP and 6.7 mg of ammonium citrate dibasic in 1.0 mL 
of 50% acetonitrile.  
To overcome the limitation on the intrinsic property of miRNA, i.e. the molecular 
masses of digested miRNA fragments, an alternative approach to create a unique mass 
signature was developed (Figure 2.1b). The goal is to create a mass signature which is 
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independent on the intrinsic property of miRNA being analyzed. To achieve this goal, the 
target miRNA was first captured by using a complementary DNA probe. This was 
followed by using the upstream sequence of the DNA probe as a single-stranded template 
and combined with the activity of DNA polymerase to extend the captured miRNA from 
its 3' end. The outcome of this enzymatic 3’ extension include: (1) using the substrate 
requirements of DNA polymerase to ensure the double-stranded portion of the duplex 
between miRNA and DNA probe was free from any mismatch of base pairs (Lee et al. 
2008); (2) with appropriate selection on the upstream sequence of DNA probe and the 
complementary deoxyribonucleotide triphosphate substrate that were available to the 3' 
extension of miRNA, it ensured the annealing of miRNA was at the correct position on 
the DNA probe, otherwise the 3' extension of miRNA could not occur properly; and (3) 
the number and type of deoxribonucleotide that would be incorporated to the 3' end of 
miRNA were controlled by the upstream sequence of DNA probe and the available 
complementary deoxyribonucleotide triphospate substrate in the 3’ extension reaction. As 
a result, an extended miRNA with a unique molecular mass was created, which is defined 
as an extended mass signature in this study. The extended mass signature is expected to 
have a different molecular mass when compare to the molecular masses of any other 
miRNA within the same sample. Recently, the ability of various DNA polymerases to 
accept an RNA fragment as a primer and the effectiveness to enzymatically incorporate 
different modified or labeled nucleotides to the 3’ end of the RNA fragment have been 
examined (Sun et al. 2009), (Purohit et al. 2003). Five different DNA polymerases were 
evaluated, which included DNA polymerase I, Klenow fragment (3′→5′ exo
−
), Bst DNA 
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polymerase, Therminator DNA polymerase, and Taq DNA polymerase. Among them, 
only Taq DNA polymerase could not use RNA as a primer. Whereas, Klenow Fragment 
(3´→5´ exo
−
) had shown the highest efficiency for nucleotide incorporation. In this study, 
Klenow fragment (3´→5´ exo
−
) was selected to extend the captured miRNA. With the 
direct MS measurements, the 3’ extension of miRNA could be extended with unmodified 
or unlabeled nucleotides. Following the 3’ extension, the miRNA-DNA probe duplex was 
immobilized on oligo dT coated magnetic beads. After that, all the reagents from 3’ 
extension were washed off, and the extended miRNA was eluted. Although the extended 
miRNA could be detected by several other MS techniques, MALDI-TOF MS was 
selected for the same reasons that have already mentioned earlier in this report. For the 
proof of concept, the same miRNA biomarker for glioblastoma, miR-183, and the 
corresponding DNA probe were used. The experimental protocol for creating the 
extended mass signature of miR-183 was systematically optimized. In comparison to a 
similar protocol for 3’ extension that has been reported earlier, the amount of starting 
material i.e. miRNA was cut down by half to 20 pmol per assay, and the incubation time 
for 3’ extension was reduced from 60 min to 20 min (Sun et al. 2009). For achieving the 
highest signal-to-noise ratio from using MALDI-TOF MS to measure the extended miR-
183, the laser intensity, number of laser shots, and delayed time for ion extraction were 
optimized. By using the optimized protocol which is described in the section of materials 
and methods, miR-183 was extended with a single nucleotide. To ensure the 3’ extension 
would be terminated after the incorporation of the first nucleotide, 2’,3-
dideoxyribonucleotide triphosphate (ddCTP) was used as the substrate for Klenow 
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fragment. The results are shown in Figure 2.8 (a). miR-183 ([miR-183+H]+ = 7084.24 
m/z); (b) miR-183 that was extended with a single nucleotide (nt) of ddC ([miR-
183+1nt+H]+ = 7357.44 m/z); and (c) miR-183 that was extended with two nucleotides, 
dC + ddT, ([miR-183+2nt+H]+ = 7661.65 m/z). In comparison to the MS measurement 
of an unextended miR-183 (Figure 2.8a), the mass difference between the extended and 
unextended miR-183 does correspond to the incorporation of an extra nucleotide to miR-
183. As shown in 2-5b, there is no detectable unextended miR-183. This confirms that all 
the miR-183 present was successfully extended. To demonstrate the flexibility of creating 
an extended mass signature, in a separate experiment, miR-183 was extended with two 
nucleotides instead of only one nucleotide. This could be achieved by using an 
appropriate mixture of two different deoxyribonucleotide triphosphate as the substrate for 
Klenow fragment (dCTP and ddTTP), which was depended on the upstream sequence of 
the DNA probe for capturing miR-183. The results that were obtained from the extension 
of miR-183 with two nucleotides are shown in Figure 2.8 (c), in which neither 
unextended miR-183 nor premature terminated extension was detected.  
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Figure 2.8. MALDI-TOF MS of (a) 1.2 pmol of unextended miR-183 ([miR-183+H]+ (b) 
miR-183 that was extended with a single nucleotide (nt) of ddC ([miR-183+1nt+H]+; and 
(c) miR-183 that was extended with two nucleotides, dC + ddT, ([miR-183+2nt+H]+ 
 
  
To confirm the specificity of creating an extended mass signature of miR-183, a 
sample that contained two different miRNA (miR-153 and miR-183) at equal 
concentration was analyzed. By using the low resolution linear MALDI-TOF MS to 
directly measure the mixture of miRNA, the two peaks that corresponded to the 
molecular ions of unextended miR-153 and unextended miR-183, respectively, could not 
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be resolved as shown in Figure 2.9 (a). This was due to the fact that the difference 
between the molecular masses of miR-153 and miR-183 is only 7.04 Da. When the 
mixture of miRNA was analyzed, both miRNA were captured by their corresponding 
DNA probe. It is important to note that the upstream sequences of the two DNA probes 
were designed to be different from each other. When only miR-183 was selectively 
extended with a single nucleotide (ddC), the same extended mass signature of miR-183 
(7357.44 m/z) as in Figure 2.9 (b) was recreated despite the presence of another miRNA 
and its corresponding DNA probe (Figure 2.9b). In the second case, the same mixture of 
miRNA was analyzed and only miR-153 was selectively extended with a single 
nucleotide (ddG). As shown in Figure 2.9 (c), a unique extended mass signature of miR-
153 (7404.51 m/z) was created while miR-183 remained unextended. 
 
Table 2.3. Molecular masses of miR-153 and miR-183 before and after extension. 
 
Oligo    Neutral Mass  
(Da) 
Positively ion  
(Da) 
Single nucleotide 
extension +ve (Da) 
Double nucleotide 
extension (Da) hsa-miR-153 7090.272 7091.280 (ddGTP) 7404.509  
hsa-miR-183 7083.232 7084.240 (dCTP)   7373.434  
hsa-miR-183 7083.232 7084.240 (ddCTP) 7357.444 (dCTP+ddTTP) 7661.650 
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Figure 2.9. MALDI-TOF mass spectrum of (a) mixture of miR-153 and miR-183, (b) 
single nucleotide extension of miR-183 in the presence of miR-153, (c) single nucleotide 
extension of miR-153 in the presence of miR-183 and (d) simultaneous single nucleotide 
extension of both miR-183 and miR-153. 
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In another experiment, both miR-153 and miR-183 were simultaneously 
extended, and the same extended mass signatures of miR-153 and miR-183 were 
recreated despite the presence of more than one particular 2’,3’-dideoxyribonculeotide 
triphosphate substrate in the 3’ extension reaction (Figure 2.9d).  
Table 2.4. Expected RNase T1 digestion fragments of extended miR-183 
Extended miR-183 UAUGGCACUGGUAGAAUUCACUddC [M-H]
-
 =  7355.433   
Cleavage position Linear phosphate (Da)  2’ 3’ cyclic phosphate (Da) Sequence 
U1:G4   1383.743   1365.728  pUAUGp 
G5:G5    362.216   344.201 Gp 
C6:G10   1607.962   1589.947  CACUGp 
G11:G11    362.216  344.201 Gp 
U12:G14    997.594   979.579  UAGp 
A15:C23   2726.737  - AAUUCACUddC 
These expected theoretical molecular masses of RNase T1 digestion from single 
nucleotide extended miR-183 in negative ion mode MS were calculated using Mongo 
Oligo Mass Calculator version 2. 
 
 
The results in Figure 2.9 b-d have also demonstrated the use of extended mass 
signature to distinguish a specific miRNA from another miRNA, which has very similar 
molecular mass. Hence, the same approach can be used to distinguish isobaric miRNA. 
Furthermore, the above results exemplify the potential of using extended mass signature 
to analyse different miRNA in one single experiment. The results from the 3’ extension 
of miR-183 was confirmed by digesting the extended miR-183 with RNase T1 as 
described earlier and the digested fragments were measured by using negative ion mode 
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MALDI-TOF MS and the results are shown in Figure 2.10. All the major peaks in the 
spectrum have been assigned to their respective digestion fragments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10. MALDI-TOF mass spectrum of extended human miR-183 after RNase T1 
digestion. 
 
 
In Figure 2.10, the peak labels without asterisks (*) represent the digested 
fragment that contains a linear 2’ phosphate group, and the peak labels with asterisks 
represent the digested fragment that contains a 2’,3’-cyclic phosphate group. The 
spectrum was obtained with THAP matrix and linear negative ion mode. The THAP 
matrix solution was prepared by dissolving 20.0 mg of 2’,3’,4’ THAP and 6.7 mg of 
ammonium citrate dibasic in 1.0 mL of 50% acetonitrile. 
 
RNase T1 is a Guanine-specific fungal endonuclease that cleaves single stranded 
RNAs, releasing oligonucleotides from the guanosine 3’ phosphate terminal (Schatz et al. 
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2004). RNase T1 digestion yields predictable sequences of known oligonucleotides and 
has been previously used by Hartmer et al to deduce the sequence of a 25 mer RNA by 
MALDI-TOF MS (Hartmer et al. 2003). As shown on Figure 2.10, RNase T1 digestion of 
oligonucleotides gives rise to 5’ cleavage fragments with a linear phosphate, however, 
2’3’ cyclic phosphates cleavage fragments that are an intermediate to the linear phosphate 
fragments are also known to coexist with the linear phosphate fragments (Hahner et al. 
1997b). The RNase T1 digestion products of extended miR-183 is shown on table 1. The 
2’3’ cyclic phosphate intermediates are 18 Da lighter in mass compared to the 3’ linear 
phosphate forms (Douthwaite and Kirpekar 2007). Both 2’3’ cyclic phosphate and linear 
phosphate fragments were observed in the extended miRNA digest as shown in Figure 
2.10.  
It has been shown that the conversion of the 2’3’ cyclic phosphate into the linear 
phosphate form occurs more readily when the identity of the nucleotide next to the last 3’ 
nucleotide is an adenosine as opposed to a uridine or cytidine. The process of ring 
opening of the cyclic phosphate can be increased by increasing the time for digestion the 
RNA or by increasing the enzyme/substrate ratio (Kirpekar et al. 2000). Although 3-HPA 
is more commonly used for the analysis of RNA, 3-HPA matrix clusters appearing in the 
low mass window may overlap with analyte peaks interfering with the analysis of spectra. 
This phenomenon has also been observed when measuring RNA fragments from RNase 
digestion (Kirpekar et al. 2000). For this reason, 2’,3’,4’ THAP matrix which exhibits 
matrix clusters in a much lower mass window was used. The peak corresponding to a 
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single guanine residue however lies within the lower end of the mass window of the 
spectrum and was therefore not identified. 
2.40 Conclusions 
Both methods for creating the mass signatures require the use of DNA probe to 
capture specific miRNA. The benefits of using the DNA probe in the future analysis of 
miRNA include to: (1) facilitate the separation of specific miRNA from a complex 
biological sample that may contain different RNA molecules, thus improving the 
accuracy on qualitative MS detection of specific miRNA; (2) allow multiple samples to 
be processed in parallel, for example in the microtiter plate format. In comparison to the 
approach of injecting samples sequentially into an LC-MS system, higher sample 
throughput can be achieved; (3) allow a sample that contains a low concentration of 
miRNA to be concentrated prior to the MS measurements. This can be achieved by either 
eluting the captured miRNA from the beads in smaller volume of water (as described in 
Materials and Methods) or start with a larger sample size and elute the capture miRNA 
from the beads in smaller volume of water; (4) no interference with MALDI MS 
measurements. The DNA capture probe does not interfere with the detection of miRNA. 
This is because the molecular mass of all DNA probe used in this study are about double 
the molecular mass of any miRNA that has been reported in the literature.  
To improve the direct MS measurements of miRNA biomarkers, the concept of 
using a unique mass signature of miRNA is introduced in this report. The feasibility of 
creating a unique mass signature was demonstrated by using either specific RNase 
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digestion or miRNA-primed extension. In comparison to matching the measured 
molecular mass of an intact miRNA molecule to the expected molecular mass, the two 
different approaches to create a unique mass signature have improved the accuracy on the 
detection of specific miRNA. Since the creation of an intrinsic mass signature has relied 
on using the DNA probe to isolate a specific miRNA prior to its digestion with the 
RNase, the concept of intrinsic mass signature is considered to be different from the 
previous reports in which only RNase digestion was used to create similar pattern of 
peaks for RNA analysis (Hossain and Limbach 2007), (Hossain and Limbach 2009; 
Banoub et al. 2010). Furthermore, the mass signature concept has also included an 
alternative approach to create a mass signature by extending miRNA from its 3’ end. The 
concept of mass signature is compatible to high throughput analysis of a specific panel of 
miRNA biomarkers. Previously, we have reported that the quantitation of nucleic acids 
by using MALDI-TOF MS was as accurate as the standard method of ultraviolet (UV) 
absorption spectrometry (Yang and Chiu 2010). Thus, the two different approaches to 
create the mass signatures can also be used to determine the amount of miRNA. 
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CHAPTER III 
TOWARDS DE NOVO SEQUENCING OF microRNA USING BOTTOM-UP 
MALDI MASS SPECTROMETRY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Schematic abstract depicting the work flow towards de novo sequencing of 
microRNA using bottom-up MALDI mass spectrometry.
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3.10 Introduction 
The increased interest in small non-coding RNA such as microRNA (miRNA) 
and small interfering RNA (siRNA) as potential targets for development of novel drugs 
(Park et al. 2009), as well as diagnostic tools for several human diseases (Calin and Croce 
2006) has raised the demand for the development of more efficient, accurate and rapid 
methods for sequencing or sequence verification of the identities of such small 
endogenous or synthetic RNAs (Wark et al. 2008), (Oberacher and Pitterl 2011). So far, 
miRNAs have been implicated in the initiation and progression of more than 160 human 
diseases including numerous cancer types, heart disease and diabetes (Jiang et al. 2009). 
Sequencing of RNA also has numerous applications in fields such as genotyping, 
forensics, elucidation of structural features as well as in the analysis of oligonucleotide-
bases for therapeutic and diagnostic purposes (Metzker 2005). New methods for 
sequencing of miRNAs can therefore be valuable tools for the development of miRNA as 
disease biomarkers or therapeutic products (Izumi et al. 2011). 
RNA sequencing can be categorized as re-sequencing, a quality control or 
confirmatory measure in which the nucleic acid sequence is already known prior to 
analysis or de novo sequencing in which case the nucleic acid sequence is unknown. 
Traditionally, de novo sequencing of RNA has been carried out by Sanger-based 
sequencing methods, in which the identity of ribonucleotide (A, U, G or C) at each 
specific position is indirectly determined by measuring a detection label that corresponds 
to one of the four ribonucleotides (Morozova and Marra 2008). Sanger sequencing has 
however been deemed too expensive, time consuming, and laborious (Metzker 2005). 
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In the past few years, several alternate methods for the sequencing of nucleic 
acids have been developed. Amongst the emerging techniques, mass spectrometry (MS) 
stands out as a very promising approach for RNA sequencing. Recent advances in mass 
spectrometry in speed, accuracy and sensitivity as well as the capability for automation 
and high throughput operation have made MS an ideal tool for nucleic acid sequencing 
(Chait 2011).. These advances can be exploited for the development of cheaper and more 
efficient methods for both re-sequencing and de novo sequencing of miRNA. As opposed 
to the conventional RNA sequencing techniques such as Sanger and next-generation-
sequencing that indirectly determine the RNA sequence by analyzing signals generated 
from secondary sources such as complementary DNA (cDNA) or fluorescence 
generation, MS offers a more direct RNA analysis by measuring mass which is an 
intrinsic property of the analyte and therefore circumvents the drawbacks associated with 
conventional RNA sequencing techniques. Moreover, MS does not require labeling or 
staining of samples prior to measurement. MS can therefore play a valuable role in the 
characterization of miRNA. An important step towards realizing the full potential of 
miRNA as therapeutic or diagnostic agents is the development of new sequencing 
methods that can be used for identification and characterization for miRNA. The 
development of such methods will provide scientists with important analytical tools and 
an opportunity to better understand gene regulatory functions of miRNA. Such tools will 
also be influential in propelling the breakthroughs in clinical diagnostics (Izumi et al. 
2011). 
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The development of various “soft” ionization techniques in MS, such as matrix-
assisted laser desorption/ionization (MALDI) and electrospray ionization (ESI), has made 
it possible to measure the molecular mass of various biomolecules. Compared to other 
MS techniques, MALDI time-of-flight MS (MALDI-TOF MS) has been the preferred ion 
source for sequence analysis of RNA. MALDI results in the generation of spectra 
dominated by singly charged ions that are relatively easy to interpret compared to spectra 
with multiply charged inns from ionization sources such as ESI (Bahr et al. 2009). 
MALDI has therefore become an important ion source for the analysis of nucleic acids 
(Fu et al. 2006). 
Here we report an approach to bottom-up sequencing of miRNA based upon 
partial hydrolysis and MALDI-MS. The temperature and time profile required to achieve 
partial miRNA hydrolysis with sufficient fragments yield and strong enough mass 
spectrometric signals to enable 100% sequence assignment were determined. De novo 
sequencing was carried out by using a ladder sequence determined from the mass 
differences between the monoisotopic peaks of the miRNA fragments combined with 
calculation of the base compositions of each fragment from exact mass measurements.  A 
third approach is proposed based upon the average isotopic composition of a hypothetical 
average nucleotide “averageotide”, analogous to the “averagine” method described by 
Senko, Beu and McLafferty for interpreting mass spectra of proteins and peptides (Senko 
et al. 1995).   
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3.20 Materials and Methods 
Three synthetic RNA oligos shown in Table 3.1 were synthesized and HPLC purified by 
Integrated DNA Technologies (San Diego, CA, USA). 
Table 3.1. Names, accession numbers and sequences of miRNAs used. 
 
2,5 Dihydroxybenzoic acid (2,5 DHB) was purchased from Acros Organics 
(Morris Plains, NJ, USA). 3-hydroxypicolinic acid (3-HPA), sinapinic acid (SA), 
ammonium acetate and ammonium citrate dibasic were acquired from Sigma Aldrich (St. 
Louis, MO, USA). Acetonitrile and methanol, both of HPLC grade were obtained from 
Fisher Scientific (Pittsburgh, PA, USA). Non-sterile 0.22 µm low protein binding 
Durapore (PVDF) syringe driven membrane filter units (25mm) were purchased from 
Millipore Corp. (Bedford, MA, USA). Nanopure water from a Barnstead NANOpure 
Diamond Water Purification System (Dubuque, Iowa, USA) was used for the 
reconstitution and dilution of RNA oligos. The deionized water was autoclaved at 250 °F 
for 30 minutes. 
miRNA name Accession number Sequence (5’3’) 
hsa-miR-153 MIMAT0000439 5’ p-UUGCAUAGUCACAAAAGUGAUC-OH 3’ 
hsa-miR-183-5p MIMAT0000261 5’ p-UAUGGCACUGGUAGAAUUCACU-OH 3’ 
mml-miR-124a MIMAT0002470 5’ p-UUAAGGCACGCGGUGAAUGCCA-OH 3’ 
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3.21 Preparation of saturated MALDI matrices for hydrolyzing  miRNA  
The three MALDI matrices namely 3-HPA, SA and 2,5 DHB were separately 
dissolved in 10% and 50% acetonitrile to saturation by vortexing. The matrices were 
centrifuged and the saturated supernatant was drawn for hydrolysis of miRNA.. Saturated 
matrices were freshly before use. 
 
3.22 Preparation of MALDI matrices for measuring hydrolyzed miRNA  
MALDI matrices that were used for analysis of the hydrolyzed miRNA were 
prepared using standard procedures available in literature. 3-HPA was prepared by 
dissolving 35.0 mg of 3-HPA and 8.80 mg of ammonium citrate dibasic in 1.0 mL of 
10% acetonitrile (Chiu 2009). 2,5 DHB was prepared by dissolving 20.0 mg of 2,5 DHB 
and 8.80 mg of ammonium citrate dibasic in 1.0 mL of 50% acetonitrile (Krause et al. 
1999). Sinapinic acid was prepared by dissolving 10.0 mg of SA and 8.80 mg of 
ammonium citrate dibasic in 1.0 mL of 50% acetonitrile (Onnerfjord et al. 1998). The 
matrix solutions were vortexed for 1-2 minutes, filtered through 0.22 µm Durapore 
membrane filter and stored at −20 °C.  
 
3.23 Preparation of hydrolyzed miRNA for MS measurement 
For the partial hydrolysis of miRNA, a 2 µL solution containing 20 pmol of 
miRNA was mixed with 2 µL of saturated MALDI matrix. The mixture was incubated in 
65 
 
a thermocycler at 55, 65, 70 or 75 °C, aliquots of each sample were drawn after 30 and 60 
minutes incubation and analyzed by MALDI-MS. The samples were prepared by the 
thin-layer technique as detailed by Barnes and Chiu (Chiu 2009). The stainless steel 
MALDI plate was cleaned with water and methanol. 0.3 µL of MALDI matrix was 
spotted on a MALDI sample plate and allowed to air dry before 0.3 µL of sample that 
had been hydrolyzed using the same type of matrix laid down on the plate was then 
spotted on top of the dried matrix and also allowed to air dry. The sample size 
corresponds to 3 pmol of miRNA. 
 
3.24 Low-resolution MALDI- TOF MS  instrument settings 
AB 4700 MALDI-TOF/TOF mass spectrometer (Proteomics Analyzer, Applied 
Biosystems, Framingham, MA) was used for low-resolution MS measurements to 
develop and optimize the hydrolysis procedure. Each sample was measured by using the 
linear high mass positive or negative mode in the 4000 Series Explorer Version 3.0 
software. The Nd:YAG laser (200 Hz) was set at 5000 arbitrary units. (maximum setting 
= 7900). The focus mass was the mass of an expected molecular ion from each sample. 
Molecular ions were extracted from the ion source after 400 ns delay. The accelerating 
voltage was +20.0 kV and grid voltage was +18.8 kV. The instrument was equipped with 
a 200 Hz digitizer. The sampling bin size was 0.5 ns with an input bandwidth of 500 
MHz, and a vertical full scale of 500 mV. The linear detector voltage was +2.0 kV. The 
pressure inside the entire instrument was maintained at the level of 10
−8
 Torr. Each 
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spectrum was automatically acquired by accumulating the results of 3000 shots with 
random edge-biased positioning of each laser shot. By using the Data Explorer Version 
4.6 software, resulting mass spectra were internally calibrated. 
 
3.25 High Resolution JMS-S3000 SpiralTOF instrument settings 
A second MALDI-TOF/TOF mass spectrometer (JMS-S3000 SpiralTOF™, JEOL 
Ltd., Tokyo, Japan) was used for high-resolution MS measurements. The SpiralTOF 
mass spectrometer is based on a unique multi-turn ion optic design that provides a very 
long (17-meter) flight path with high ion transmission efficiency (Satoh et al. 2011), 
(Satoh et al. 2007),
 
(Satoh et al. 2006). The Spiral TOF measurements took place in a 
separate laboratory (JEOL USA, Inc. 11 Dearborn Road, Peabody, MA 01960, United 
States) and the samples were coded and not identified by their miRNA name. 
Using the sample preparation method described under materials and methods, 
samples were spotted onto a special 384-well plate that contains one additional external-
reference spot for every four sample spots. A Nd-YLF laser with a wavelength of 349 nm 
operated at 500 Hz was used to desorb and ionize the samples.  Data from 250,000 laser 
shots were accumulated for each mass spectrum. The extraction delay (250 ns) and the 
laser power were optimized to maximize the separation of the analyte isotope peaks. A 
peptide mixture containing Angiotensin I, Angiotensin II, P14R, ACTH 1-17, ACTH 18-
39, insulin chain B oxidized and bovine insulin was used as an external calibration 
standard for exact mass measurements.  
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JEOL MS Tornado software was used to process the Spiral TOF mass spectra. 
Ladder sequences were determined from the mass differences between successive 
fragments by using native functions in the MS Tornado software and by using New MS 
Tools software (RBC Software) to examine mass spectra exported in text format. 
Nucleotide compositions were calculated by New MS Tools software.  A Microsoft 
Visual Basic program was written to calculate the average nucleotide distribution for the 
human miRNA sequences in the miRNA database.  Averageotide calculations were 
carried out in a Microsoft Excel spreadsheet.  All spectra shown, both from the AB 
MALDI-TOF and the Spiral TOF were obtained in the positive ion mode. 
  
3.30 Results and Discussion 
Analysis of samples by MALDI requires that the samples be co-crystallized with 
a large molar excess of a matrix. The purpose of the matrix is to strongly absorb light in 
ultraviolet region (for UV laser MALDI) or infrared region (for IR laser MALDI) in 
order to desorb the analyte. The matrix also acts as a proton donor or receptor during the 
positive or negative ionization process of the sample respectively. The most commonly 
used MALDI matrices for RNA analysis are small weak organic acids such as sinapinic 
acid (SA), 2,5 Dihydroxybenzoic acid (2,5 DHB) and 3-hydroxypicolinic acid (3-HPA). 
The structures and pKas of these matrices are shown on Figure 3.2. The acidic nature of 
MALDI matrices presents a unique opportunity for the development of miRNA 
sequencing assays. We explored the ability of acidic MALDI matrices to hydrolyze 
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miRNA in order to create fragments that resemble sequencing ladders prior to measuring 
the hydrolyzed mixture using MALDI-TOF MS. Usually hydrolysis of RNA has 
previously been done suing various chemicals such as trifluoroacetic acid, however, these 
external additives have been shown to affect the ionization efficiency of nucleic acid, 
leading to the suppression of signal. It is therefore important that solvents and additives 
that do not affect the MALDI process be used for the success of RNA sequencing (Izumi 
et al. 2011). 
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O  
SA (pKa = 4.53)                              2,5 DHB (pKa = 3.01)                  3-HPA (pKa = 1.14)                  
Figure 3.2. Chemical structures and pKa values of common MALDI matrices. 
Since the developed assay utilizes the traditional MALDI matrix reagents which 
have been optimized for MALDI-MS measurements, interference from external sources 
and hence contamination and signal suppression is minimized. 
It has been known for many years that RNA is susceptible to acidic hydrolysis 
through the cleavage of its phosphodiester bonds. The RNA hydrolysis mechanism 
proceeds through two stages as shown in Figure 3.3. In the first step, the phosphoryl 
oxygen is rapidly protonated, followed by a nucleophilic attack by the 2’ hydroxyl on 
phosphorus to form an intermediate trigonal-bipyramidal phosphane. In the second step, 
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transfer of a proton to the 5’ oxygen directs the departure of the 5’ linked nucleotide, 
causing cleavage of the phosphodiester bond (Perreault and Anslyn 1997). The hydrolysis 
therefore leads to two sequencing ladders. The first ladder carries the original 5’ 
phosphate group and a 3' phosphate at the cleavage site; these fragments are termed here 
as the 5’ ladder, while the other ladder carries the original 3’ hydroxyl group and a 5’ 
hydroxyl at the cleavage site and are termed here as the 3’ ladder. The hydrolysis 
products are independent of pH but the yield of products is pH depended (Oivanen et al. 
1998). 
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Figure 3.3. Schematic diagram for the acidic hydrolysis of RNA. 
 
 
3.31 Re-sequencing results obtained using low resolution MALDI MS 
For the initial hydrolysis studies, a low resolution mass spectrometer (AB 4700 
TOF/TOF) was used. The three matrices (SA, 2,5 DHB and 3-HPA) were separately 
dissolved in 10% acetonitrile and incubated with miR-153 at 60 °C as explained in 
materials and methods. To maximize the hydrolysis process, the matrices were dissolved 
to saturation. After the hydrolysis, the resulting fragments were then analyzed by MS. 
The mass difference between adjacent peaks were calculated and matched to known 
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nucleotide masses. The results on sequence coverage achieved by hydrolyzing miR-153 
using saturated SA, 2,5 DHB and 3-HPA at 60° C for 30 minutes and 60 minutes are 
shown in Figure 3.4. Analysis of the hydrolysis products after 30 minutes of incubation 
for SA, 2,5 DHB and 3-HPA yielded 22.7%, 69.7% and 74.2% sequence identification 
respectively. The incubation was extended to 60 minutes and SA, 2,5 DHB and 3-HPA 
yielded 45.5%, 62.1% and 83.3% sequence identification respectively. The matrices were 
dissolved in 50% acetonitrile and the experiments repeated. The results of sequence 
identification for SA, 2,5 DHB and 3-HPA at 30 min and 60 min incubation were 18.2%, 
25.7%, 65.2% and 36.4%, 27.5%, 72.7% respectively. 
There was a notable decrease in sequence identification when the matrices were 
dissolved in 50% compared to 10% acetonitrile. It is a well-known fact that for aqueous-
organic solvents, the composition of the solvent has a profound effect on the degree of 
dissociation of any dissolved ionizable compounds. In the case of carboxylic acids such 
as SA, 2,5 DHB and 3-HPA, the pKa of these matrices increases with increasing content 
of acetonitrile. Consequently, the pH of the saturated matrices increases as the 
acetonitrile content is increased (Padró et al. 2012). As Oivanen et al noted, the yield of 
the hydrolysis products is pH dependent (Oivanen et al. 1998). Based on this 
phenomenon, it was hypothesized that the pKa of the saturated MALDI matrices 
dissolved in 10% acetonitrile is considerably lower and so is the pH when compared with 
matrices dissolved in 50% acetonitrile. Subsequently, a higher yield of the miRNA 
hydrolysis fragments was achieved when using solutions dissolved in 10% acetonitrile 
translating to a higher sequence coverage. The results shown in Figure 3.4 are 
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representative of a triplicate measurement in which all three acquired spectra were used 
to determine the sequence coverage. From Figure 3.4, when comparing the ability of 
three matrices for the hydrolysis of miRNA to create sufficient 3’ and 5’ ladders for the 
sequencing of miRNA 3-HPA hydrolysis gave the highest percent sequence coverage 
compared to SA and 2,5 DHB. 
For the optimization of the yield of hydrolysis products, the hydrolysis 
temperature and time were also investigated. The temperature profile for miR-153 
hydrolysis using 3-HPA was performed on the AB MALDI-TOF by incubating miR-153 
with saturated 3-HPA at 55, 60, 65, 70 and 75 °C, and measuring the samples after 30 
and 60 minute durations. As shown in Figure 3.5 the sequence identification for the five 
temperature settings after 30 minute and 60 minutes hydrolysis was 40.9, 74.2, 89.4, 
84.9, 77.2% and 59.1, 84.9, 81.8, 74.2, 71.2% respectively.  
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Figure 3.4. Sequence coverage achieved by hydrolyzing miR-153 using saturated SA, 2,5 
DHB and 3-HPA at 60° C.  
 
 
Minimal hydrolysis of the control samples was observed at 55, 60 and 65 °C; 
however, this rate doubled when the temperature was elevated to 70 and 75 °C. The 
increased hydrolysis is attributable to the elevated incubation temperature. The results 
shown in Figure 3.5 are representative of a triplicate measurement in which all three 
acquired spectra were used to determine the sequence coverage.  Hydrolysis of miR-153 
using 3-HPA saturated in 10% acetonitrile at 65°C for 30 minutes yielded the highest 
sequence identification, these conditions were therefore used for all subsequent 
hydrolysis experiments. 
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Figure 3.5. Sequence coverage achieved by incubation of miR-153 with 3-HPA in 
saturated 10% acetonitrile at different temperatures. 
 
 
From the previous results in figure 3.4, it was observed that higher sequence 
coverage was obtained when the matrices were dissolved in 10% acetonitrile compared to 
50% acetonitrile. Figure 3.6, 3.7 and 3-8 shows mass spectra resulting from the AB 
MALDI-TOF analysis of miR-153 using SA, 2,5 DHB and 3-HPA dissolved in 10% 
acetonitrile respectively. The hydrolysis was performed at 60 °C. The solid lines are used 
to identify the 3’ ladder and the dashed lines are used to identify the 5’ ladder. The 
overall sequence coverage achieved using SA, 2,5 DHB and 3-HPA when considering 
only one spectrum was 72.7%, 81.8% and 81.9% respectively, however, when 
considering the three replicate spectra from a single measurement, the sequence coverage 
obtained from SA, 2,5 DHB and 3-HPA was 72.7%, 81.8% and 89.4% respectively.  In 
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deciding the best matrix to use for the hydrolysis of miRNA, several factors were taken 
into consideration 1) it was noted that spectra from SA and 2,5 DHB had wider peaks and 
therefore poor mass resolution which presents a challenge to assignment of nucleotide 
sequences especially for ladders differing by a single U or C nucleotide. 2) the overlap of 
the two ladders reinforce and support the sequence deduction, and it was noted that 
although the spectra from both SA and 2,5 DHB had more 5’ ladder fragments, they 
exhibited fewer overall 3’ ladders when compared to 3-HPA ladders and 3) spectra 
resulting from SA and 2,5 DHB hydrolysis showed some peaks that could not be 
assigned to neither the 5’ nor the 3’ ladder. It is hypothesized that these unassigned 
fragments could be as a result of base loss from the miRNA fragments. Based on these 
facts, 3-HPA was selected as the most suitable matrix for the hydrolysis and sequence 
determination of miRNA. 
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5’ p-UUGCAUAGUCACAAAAGUGAUC-OH 3’ 
 
 
 
Figure 3.6. Mass spectrum of miR-153 hydrolyzed using saturated SA in 10% acetonitrile 
at 60 °C. 
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5’ p-UUGCAUAGUCACAAAAGUGAUC-OH 3’ 
 
 
Figure 3.7. Mass spectrum of miR-153 hydrolyzed using saturated 2,5 DHB in 10% 
acetonitrile at 60 °C. 
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5’ p-UUGCAUAGUCACAAAAGUGAUC-OH 3’ 
 
Figure 3.8. Mass spectrum of miR-153 hydrolyzed using saturated 3-HPA in 10% 
acetonitrile at 60 °C. 
 
 
Mass accuracy calculations of 5’ ladder obtained from the hydrolysis of miR-153 
using 3-HPA saturated in 10% acetonitrile on the AB MALDI-TOF (low resolution) are 
shown in Table 3.2. The average mass accuracy using the singly charged average mass 
peaks was 59.65 ppm. It is important to note the mass accuracy achieved when using the 
AB 4700 TOF/TOF mass spectrometer was not sufficient to distinguish fragments 
differing by a U or C nucleotide due to the low resolution. Since the sequence of miR-
153 was known prior to the, this experiment is considered as a sequence confirmation i.e. 
re-sequencing. 
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Table 3.2. Mass accuracy of 3’ ladder fragments from hydrolyzed miR-153 
3’ Ladder Theoretical 
average m/z  
Observed 
average m/z  
Mass 
difference 
Mass accuracy 
(ppm) 
GAUC 1223.806 1223.7589 0.0471 38.486 
UGAUC 1529.975 1529.9674 0.0076 4.967 
GUGAUC 1875.184 1875.2865 0.1025 54.661 
AGUGAUC 2204.393 2204.4194 0.0264 11.976 
AAGUGAUC 2533.602 2533.5078 0.0942 37.180 
AAAGUGAUC 2862.811 2862.4785 0.3325 116.144 
AAAAGUGAUC 3192.02 3192.3406 0.3206 100.437 
CAAAAGUGAUC 3497.203 3497.7473 0.5443 155.638 
ACAAAAGUGAUC 3826.413 3826.6326 0.2196 57.390 
CACAAAAGUGAUC 4131.597 4131.3413 0.2557 61.888 
UCACAAAAGUGAUC 4437.766 4437.344 0.422 95.092 
GUCACAAAAGUGAUC 4782.974 4783.127 0.153 31.988 
AGUCACAAAAGUGAUC 5112.183 5112.2466 0.0636 12.440 
UAGUCACAAAAGUGAUC 5418.352 5418.9697 0.6177 114.001 
AUAGUCACAAAAGUGAUC 5747.561 5747.9619 0.4009 69.751 
CAUAGUCACAAAAGUGAUC 6052.745 6052.512 0.233 38.494 
GCAUAGUCACAAAAGUGAUC 6397.954 6397.594 0.36 56.267 
UGCAUAGUCACAAAAGUGAUC 6704.123 - - - 
pUUGCAUAGUCACAAAAGUGAUC 7090.272 7090.392 0.12 16.924 
Average mass accuracy 59.651 ppm 
The sequencing ladder was obtained from low resolution AB 4700 MALDI 
measurements of miRNA hydrolyzed at 60 °C using 3-HPA saturated in 10% acetonitrile. 
 
 
3.32 De novo sequencing results obtained using JMS-S3000 SpiralTOF 
The approach of assigning nucleic acid sequences using mass differences from 
mass spectral data of nucleic acids was proposed in 1993 by Pieles et al (Pieles et al. 
1993) and has become a well-established procedure for interpreting sequence data from 
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sequencing ladders. The application of mass differences technique to assign RNA 
sequences has however been much slower compared to its use for DNA sequences. 
Sequencing of DNA is easier partly because of the large minimum mass difference 
between the nucleotides adenosine and thymine (>9 Da), compared to the minimum mass 
difference between RNA nucleotides uracil and cytidine (1 Da). It is therefore easier to 
unambiguously assign sequence information to fragments of DNA compared to RNA due 
to limitations in instrument resolving power (Tolson and Nicholson 1998). To overcome 
this challenge, the JMS-S3000 SpiralTOF MALDI MS which can attain a resolution of 
>60,000 over a large mass range was used in this study for de novo sequencing of 
miRNA (Satoh et al. 2007). The three miRNAs (miR-183, miR-124 and miR-153) were 
hydrolyzed using, 3-HPA saturated in 10% acetonitrile at 65 
0
C for 30 minutes and the 
resulting mass ladders analyzed using the JMS-S3000 SpiralTOF. The mass differences 
between adjacent ladder peaks were calculated and matched against the known mass of 
ribonucleotides A, U, G and C. Once a match was found, the nucleotide was assigned to 
the mass difference. This was done for both the 5’ and 3’ sequence ladders.  
Following the establishment of the optimal miRNA hydrolysis conditions using 
MALDI matrices with low resolution mass spectrometry, the developed method was 
tested on two coded blind samples of hsa-miR-183 (miR-183) and mml-miR-124 (miR-
124). The two miRNAs were analyzed by a separate laboratory (JEOL USA, Inc. 11 
Dearborn Road, Peabody, MA 01960, United States). The sequence elucidation of the 
blind samples is therefore considered de novo sequencing of miRNA. In addition to the 
two blind samples, miR-153 which was used as a model in the low resolution 
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optimization studies was also analyzed in the same laboratory. To establish the resolution 
and mass accuracy at high molecular weight, the two intact miRNAs, miR-183 and miR-
124 were measured by the JMS-S3000 SpiralTOF. Theoretical simulation of mass spectra 
for the molecular ions of miR-183 and miR-124 was generated using msTornado Analysis 
software and were compared to the measured spectra. Figure 3.9 (a) and (b) are the 
measured and theoretical mass spectra of miR-183 while 3-10 (a) and (b) represent the 
measured and theoretical mass spectra of miR-124. The mass accuracy obtained for the 
molecular ions of miR-183 and miR-124 is tabulated in table 3.3 and 3-4 respectively. A 
mass accuracy of 4.1705 ppm and 9.5590 ppm were achieved for miR-183 and miR-124 
respectively. In each case, isotopic resolution was achieved with a resolving power of 
20,000 full width half maximum (FWHM). 
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Figure 3.9. (a) Measured and (b) theoretical simulation of isotopic distribution of [miR-
183 + H]
+ 
. 
 
 
Table 3.3. Mass accuracy attained on the isotopic distribution of miR-24 
 
Measured Mass (M) Theoretical Mass (T) M-T Mass Accuracy 
7080.8800 7080.9124 -0.0324 4.5756 
7081.8895 7081.9151 -0.0256 3.6148 
7082.8955 7082.9177 -0.0222 3.1343 
7083.8958 7083.9202 -0.0244 3.4444 
7084.8984 7084.9227 -0.0243 3.4298 
7085.8998 7085.9252 -0.0254 3.5845 
7086.9001 7086.9276 -0.0275 3.8803 
7087.9059 7087.9300 -0.0241 3.4001 
7088.9069 7088.9324 -0.0255 3.5971 
7089.8967 7089.9348 -0.0381 5.3738 
7090.8816 7090.9372 -0.0556 7.8409 
Average mass accuracy 4.1705 ppm 
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Figure 3.10. (a) Measured and (b) theoretical simulation of isotopic distribution of [miR-
124 + H]
+
. 
 
  
Table 3.4. Mass accuracy attained on the isotopic distribution of miR-124 
 
Measured Mass (M) Theoretical Mass (T) M-T Mass Accuracy 
7157.8839 7157.9488 -0.0649 9.0668 
7158.8850 7158.9515 -0.0665 9.2890 
7159.8896 7159.9540 -0.0644 8.9944 
7160.8939 7160.9566 -0.0627 8.7558 
7161.8951 7161.9590 -0.0639 8.9221 
7162.8948 7162.9615 -0.0667 9.3117 
7163.8957 7163.9639 -0.0682 9.5198 
7164.9006 7164.9663 -0.0657 9.1696 
7165.8954 7165.9687 -0.0733 10.2289 
7166.8957 7166.9771 -0.0814 11.3576 
7167.8979 7167.9734 -0.0755 10.5329 
Average Mass accuracy  9.5590 ppm 
 
 
Figure 3.11 is a MALDI mass spectrum of partially hydrolyzed miR-183 obtained 
using the high resolution JMS-S3000 SpiralTOF. 3-10(a) shows the peaks that 
correspond to the 5’ ladder while 3(b) shows peaks that correspond to the 3’ ladder. In 
total, 17 unique 5’ fragments and 18 unique 3’ fragments as well as the precursor ion of 
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miR-183 were identified. In the sequence above Figure 3.11 (a) the fragments identified 
in the 5’ ladder are underlined while those identified in the 3’ ladder are overlined. Since 
the sequencing can done from both the 5’ and 3’ ladders, the two ladders overlap and 
complement each other e.g. the bolded region in the sequence above Figure 3.11 
represents a 59.1% sequence overlap between the 5’ and 3’ ladders of miR-183. Besides 
increasing the confidence of making the correct sequence identification, the intrinsic 
degeneracy provided by the two overlapping ladders makes it possible to deduce the 
sequence of a miRNA even in cases where all the fragment peaks are not detected from 
one sequencing ladder. Isotopic resolution of the hydrolyzed fragments was achieved and 
the results of the isotopic distribution of selected peaks are shown in Figure 3.12, with the 
3’ ladder subspectra being marked with *. The resulting hydrolyzed fragments, their 
theoretical masses, observed mass, difference between theoretical and observed masses as 
well as the mass accuracy for both 5’ and 3’ ladders for miR-183 are tabulated in Tables 
3-5 and 3-6 respectively. The 5’ ladder was detected with an average mass accuracy of 
2.11 ppm while for the 3’ ladder, an average mass accuracy of 1.95 was attained.   
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Figure 3.11. (a) 5’ ladder and (b) 3’ ladder of hydrolyzed miR-183 obtained using the 
JMS-S3000 SpiralTOF. 
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Figure 3.12. Subspectra from 5’ and 3’ ladders of hydrolyzed miR-183 showing the 
isotopic resolution. 
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Table 3.5. Mass accuracy of 5’ ladder fragments from hydrolyzed miR-183 
5’ Ladder  Theoretical 
Mass 
(Da) 
Observed 
Mass 
(m/z) 
Mass 
Difference 
(Da) 
Mass 
Accuracy 
(ppm) 
pUAUG 1367.12416 1367.1172 0.007  5.09  
pUAUGG 1712.17160 1712.1729 -0.001  -0.76  
pUAUGGC 2017.21289 2017.2159 -0.003  -1.49  
pUAUGGCA 2346.26540 2346.2705 -0.005  -2.17  
pUAUGGCAC 2651.30669 2651.3093 -0.003  -0.98  
pUAUGGCACU 2958.33471 2958.3404 -0.006  -1.92  
pUAUGGCACUG 3303.38212 3303.3896 -0.007  -2.26  
pUAUGGCACUGG 3648.42954 3648.4383 -0.009  -2.40  
pUAUGGCACUGGU 3954.45486 3954.4617 -0.007  -1.73  
pUAUGGCACUGGUA 4283.50736 4283.5116 -0.004  -0.99  
pUAUGGCACUGGUAG 4628.55479 4628.5570 -0.002  -0.48  
pUAUGGCACUGGUAGA 4958.60982 4958.6071 0.003  0.55  
pUAUGGCACUGGUAGAA 5287.66233 5287.6549 0.007  1.41  
pUAUGGCACUGGUAGAAU 5593.68767 5593.6738 0.014  2.48  
pUAUGGCACUGGUAGAAUU 5899.71301 5899.6895 0.024  3.98  
pUAUGGCACUGGUAGAAUUC 6204.75431 6204.7474 0.007  1.11  
pUAUGGCACUGGUAGAAUUCA 6533.80681 6533.7727 0.034  5.22  
pUAUGGCACUGGUAGAAUUCAC 6838.84811 6838.8370 0.011  1.62  
pUAUGGCACUGGUAGAAUUCACU 7083.92021 7083.8958 0.024  3.45  
Average mass accuracy     2.11 ppm 
The sequencing ladder was obtained from high resolution MALDI SpiralTOF 
measurements of miRNA hydrolyzed at 65 °C using 3-HPA saturated in 10% acetonitrile. 
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Table 3.6. Mass accuracy of 3’ ladder fragments from hydrolyzed miR-183 
3’ Ladder Theoretical 
Mass  
(Da)
 
 
Observed 
Mass  
(m/z)
 
 
Mass 
Difference 
(Da) 
Mass 
Accuracy 
(ppm) 
UCACU 1490.23721 1490.2265 0.011  7.19  
UUCACU 1796.26251 1796.2595 0.003  1.68  
AUUCACU 2125.31503 2125.3164 -0.001  -0.64  
AAUUCACU 2454.36755 2454.3708 -0.003  -1.32  
GAAUUCACU 2800.41769 2800.4129 0.005  1.71  
AGAAUUCACU 3129.47019 3129.4777 -0.008  -2.40  
UAGAAUUCACU 3435.49552 3435.5030 -0.007  -2.18  
GUAGAAUUCACU 3780.54293 3780.5527 -0.010  -2.58  
GGUAGAAUUCACU 4125.59035 4125.5964 -0.006  -1.47  
UGGUAGAAUUCACU 4431.61567 4431.6252 -0.010  -2.15  
CUGGUAGAAUUCACU 4737.65953 4737.6605 -0.001  -0.20  
ACUGGUAGAAUUCACU 5066.71203 5066.7152 -0.003  -0.63  
CACUGGUAGAAUUCACU 5371.75334 5371.7521 0.001  0.23  
GCACUGGUAGAAUUCACU 5716.80076 5716.7911 0.010  1.69  
GGCACUGGUAGAAUUCACU 6061.84818 6061.8345 0.014  2.26  
UGGCACUGGUAGAAUUCACU 6367.87351 6367.8602 0.013  2.09  
AUGGCACUGGUAGAAUUCACU 6696.92076 6696.9123 0.008  1.26  
pUAUGGCACUGGUAGAAUUCACU 7083.92021 7083.8958 0.024  3.45  
Average mass accuracy       1.95 ppm 
The sequencing ladder was obtained from high resolution MALDI SpiralTOF 
measurements of miRNA hydrolyzed at 65 °C using 3-HPA saturated in 10% acetonitrile. 
 
 
Figure 3.13 shows the resulting hydrolyzed fragments for miR-124. The 5’ and 3’ 
ladders are shown in Figure 3.14 (a) and (b) respectively. The bolded region in the 
sequence above Figure 3.14 represents a 63.6% sequence overlap between the 5’ and 3’ 
ladders of miR-124, further reinforcing the sequence determined. Isotopic resolution of 
the hydrolyzed fragments was achieved and the results of the isotopic distribution of 
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selected peaks are shown in Figure 3.15. The theoretical masses, observed mass, 
difference between theoretical and observed masses as well as the mass accuracy for both 
5’ and 3’ ladders for miR-124 are tabulated in Tables 3-7 and 3-8 respectively. The 5’ 
ladder was detected with an avreage mass accuracy of 4.32 ppm while for the 3’ ladder, 
an avreage mass accuracy of 4.29 was attained.   
 
 
Figure 3.13. Spiral TOF MALDI MS spectrum of 5’ and 3’ fragments obtained from the 
hydrolysis of miR-124a using 3-HPA saturated in 10% acetonitrile in postive ion mode. 
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miR-124 sequence       pUUAAGGCACGCGGUGAAUGCCA 
 
Figure 3.14. Spiral TOF MALDI MS spectrum of miR-124a fragments obtained from the 
hydrolysis of using 3-HPA saturated in 10% acetonitrile in positive ion mode.  
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Figure 3.15. Spiral TOF MALDI MS spectrum showing the fragments obtained from the 
hydrolysis of miR-124. 
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Table 3.7. Mass accuracy of 3’ ladder fragments from hydrolyzed miR-124. 
3’ Ladder Theoretical 
m/z 
Observed 
m/z 
Mass 
difference 
Mass 
accuracy (ppm) 
GCCA 1223.23404 1223.2338 0.000  0.20  
UGCCA 1529.25934 1529.2593 0.000  0.03  
AUGCCA 1858.31186 1858.3117 0.000  0.09  
AAUGCCA 2187.36438 2187.3645 0.000  -0.05  
GAAUGCCA 2532.41181 2532.4133 -0.001  -0.59  
UGAAUGCCA 2839.43977 2839.4394 0.000  0.13  
GUGAAUGCCA 3184.48455 3184.4883 -0.004  -1.18  
GGUGAAUGCCA 3529.53461 3529.5303 0.004  1.22  
CGGUGAAUGCCA 3834.57591 3834.5707 0.005  1.36  
GCGGUGAAUGCCA 4179.62334 4179.6175 0.006  1.40  
CGCGGUGAAUGCCA 4484.66463 4484.6522 0.012  2.77  
ACGCGGUGAAUGCCA 4814.71966 4814.6975 0.022  4.60  
CACGCGGUGAAUGCCA 5119.76097 5119.7339 0.027  5.29  
GCACGCGGUGAAUGCCA 5464.80839 5464.7706 0.038  6.92  
GGCACGCGGUGAAUGCCA 5809.85582 5809.8023 0.054  9.21  
AGGCACGCGGUGAAUGCCA 6138.90833 6138.8390 0.069  11.29  
AAGGCACGCGGUGAAUGCCA 6467.96085 6467.8988 0.062  9.59  
UAAGGCACGCGGUGAAUGCCA 6773.98618 6773.8905 0.096  14.12  
pUUAAGGCACGCGGUGAAUGCCA 7160.98035 7160.8939 0.086  12.07  
Average mass accuracy 4.32 ppm 
The sequencing ladder was obtained from high resolution MALDI SpiralTOF 
measurements of miRNA hydrolyzed at 65 °C using 3-HPA saturated in 10% acetonitrile. 
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Table 3.8. Mass accuracy of 5’ ladder fragments from hydrolyzed miR-124. 
5’ Ladder Theoretical 
m/z
 
 
Observed 
m/z
 
 
Mass 
difference 
Mass 
accuracy (ppm) 
pUUAA 1351.12925 1351.1265 0.003  2.04  
pUUAAG 1696.17668 1696.1762 0.000  0.28  
pUUAAGG 2041.22412 2041.2213 0.003  1.38  
pUUAAGGC 2346.26540 2346.2657 0.000  -0.13  
pUUAAGGCA 2675.31792 2675.3159 0.002  0.76  
pUUAAGGCAC 2981.36187 2981.3618 0.000  0.02  
pUUAAGGCACG 3326.40929 3326.4096 0.000  -0.09  
pUUAAGGCACGC 3631.45059 3631.4477 0.003  0.80  
pUUAAGGCACGCG 3976.49801 3976.4925 0.006  1.39  
pUUAAGGCACGCGG 4321.54543 4321.5400 0.005  1.26  
pUUAAGGCACGCGGU 4627.57076 4627.5533 0.017  3.77  
pUUAAGGCACGCGGUG 4973.62070 4973.6061 0.015  2.94  
pUUAAGGCACGCGGUGA 5302.67321 5302.6512 0.022  4.15  
pUUAAGGCACGCGGUGAA 5631.72573 5631.6900 0.036  6.34  
pUUAAGGCACGCGGUGAAU 5937.75106 5937.6938 0.057  9.64  
pUUAAGGCACGCGGUGAAUG 6282.79849 6282.7237 0.075  11.90  
pUUAAGGCACGCGGUGAAUGC 6587.83979 6587.7763 0.063  9.64  
pUUAAGGCACGCGGUGAAUGCC 6892.88109 6892.7921 0.089  12.91  
pUUAAGGCACGCGGUGAAUGCCA 7160.98035 7160.8939 0.086  12.07  
Average mass accuracy 4.29 ppm 
The sequencing ladder was obtained from high resolution MALDI SpiralTOF 
measurements of miRNA hydrolyzed at 65 °C using 3-HPA saturated in 10% acetonitrile. 
 
 
Using the same protocol of hydrolysis with saturated 3-HPA, analysis of partially 
hydrolyzed miR-153 was performed and the results are shown in Figure 3.16. The peaks 
in the mass spectrum that correspond to fragments that end with U or C were identified in 
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Figure 3.17, enlarged, labeled and presented in Figure 3.18. The rest of the isotopic 
distribution is shown in Figure 3.19. 
 
Figure 3.16. Spiral TOF MALDI MS spectrum of miR-153 fragments obtained from the 
hydrolysis of using 3-HPA saturated in 10% acetonitrile in positive ion mode. 
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Figure 3.17. Identification of fragments terminated by U or C from a MALDI SpiralTOF 
mass spectrum obtained from the hydrolysis of miR-153. 
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Figure 3.18. Subspectra of isotopic distribution from 3’ ladder of hydrolyzed miR-153 
with terminal C or U.  
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Figure 3.19. (a) and (b) subspectra of isotopic distribution from 3’ ladder of hydrolyzed 
miR-153  
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Table 3.9. Mass accuracy of 3’ ladder fragments from hydrolyzed miR-153. 
3’ Ladder Theoretical 
m/z  
Observed 
m/z  
Mass 
difference 
Mass accuracy 
(ppm) 
UGAUC 1530.2434 1530.2483 0.005 3.23 
GUGAUC 1875.2908 1875.3005 0.01 5.18 
AGUGAUC 2204.3433 2204.3545 0.011 5.08 
AAGUGAUC 2533.3958 2533.4084 0.013 4.96 
AAAGUGAUC 2863.451 2863.4623 0.011 3.95 
AAAAGUGAUC 3192.5035 3192.5215 0.018 5.64 
CAAAAGUGAUC 3497.5448 3497.567 0.022 6.35 
ACAAAAGUGAUC 3826.5973 3826.6238 0.027 6.93 
CACAAAAGUGAUC 4131.6386 4131.6672 0.029 6.92 
UCACAAAAGUGAUC 4437.6639 4437.6912 0.027 6.15 
GUCACAAAAGUGAUC 4783.7139 4783.7447 0.031 6.44 
AGUCACAAAAGUGAUC 5112.7664 5112.8243 0.058 11.33 
UAGUCACAAAAGUGAUC 5418.7917 5418.8373 0.046 8.41 
AUAGUCACAAAAGUGAUC 5747.8442 5747.9013 0.057 9.93 
CAUAGUCACAAAAGUGAUC 6052.8855 6052.9208 0.035 5.83 
GCAUAGUCACAAAAGUGAUC 6397.933 6397.992 0.059 9.23 
UGCAUAGUCACAAAAGUGAUC 6703.9583 6704.0421 0.084 12.5 
pUUGCAUAGUCACAAAAGUGAUC 7090.9525 7091.0328 0.08 11.33 
Average mass accuracy 7.19 ppm 
The sequencing ladder was obtained from high resolution MALDI SpiralTOF 
measurements of miRNA hydrolyzed at 65 °C using 3-HPA saturated in 10% acetonitrile. 
 
 
When using the low resolution AB 4700 TOF/TOF mass spectrometer, it was 
noted that the percentage of miRNA sequence identified was closely related to the trend 
in pKa of the matrices. 3-HPA (pKa = 1.14) produced the highest sequence coverage 
followed by 2,5 DHB (pKa = 3.01) then SA (pKa = 4.53), however, 100% sequence 
coverage was achieved when using high resolution JMS-S3000 SpiralTOF mass 
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spectrometer. This was demonstrated by using the same hydrolysis and MALDI sample 
preparation methods for the hydrolysis of miR-153 followed by measurement of the 
resultant fragments using both instruments. The sequence identification obtained from a 
single spectra using the AB MALDI-TOF was 72.7% while 100% sequence identification 
was obtained when using the JMS-S3000 SpiralTOF. The difference in sequence 
coverage observed between the AB 4700 TOF/TOF and JMS-S3000 SpiralTOF mass 
spectrometers may be attributed to the sensitivity difference between the two i.e. the low 
signal to noise ratio of the JMS-S3000 SpiralTOF enabled the detection of more 
fragments compared to the  AB 4700 TOF/TOF instrument. 
Theoretically, the 5’ and 3’ fragments are produced in equal amounts; however, 
the spectra from all three miRNAs analyzed consistently showed higher intensity of the 
3’ fragments that bear hydroxyl groups on both 5’ and 3’ termini. This phenomenon was 
also observed by Hahner et al. It has been hypothesized that there is probably a 
preferential inclusion of fragments in the MALDI matrix based on their termini or more 
likely, that there is preferential ionization of fragments during the MALDI process. There 
is however no structural differences in the 5’ and 3’ fragments that can support the 
explanation of the preference (Hahner et al. 1997a).  
3.40 Alternative Approach to Interpret JMS-S3000 SpiralTOF Data 
In the previous section, JEOL MS Tornado software was used to process the 
Spiral TOF mass spectra. Ladder sequences were determined from the mass differences 
between successive fragments by using native functions in the MS Tornado software and 
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by using New MS Tools software (RBC Software) to examine mass spectra exported in 
text format. Although the assay presented here is designed and optimized for miRNA 
whose average length is 22 nucleotides, it should also be noted that the assay could be 
applicable to longer RNA samples. It is however expected that due to instrument 
limitations on resolving power, isotopic distribution may not be achieved in all 
circumstances. Also, for analytes that are present in low concentrations, the monoisotopic 
peaks necessary for calculation of mass differences may also not be observed. Under 
these conditions, the use of mass differences between monoisotopic peaks will not be 
feasible. To tackle this challenge, an alternative approach to MS data interpretation for 
sequence elucidation was proposed. The proposed approach is based upon the average 
isotopic composition of a hypothetical average nucleotide “averageotide”, analogous to 
the “averagine” method described by Senko, Beu and McLafferty for interpreting mass 
spectra of proteins and peptides (Senko et al. 1995). Nucleotide compositions were 
calculated by New MS Tools software. A Microsoft Visual Basic program was written to 
calculate the average nucleotide distribution for the human miRNA sequences in the 
miRBase database.  Averageotide calculations were carried out in a Microsoft Excel 
spreadsheet.  The approach uses exact masses to check and confirm these sequence 
assignments. The calculation was carried out in the same manner that elemental 
compositions are typically determined from high-resolution, exact-mass measurements. 
“Pseudoelements” (labeled C,U,A,G) were defined having the isotopic composition 
(exact masses and relative abundances) of each nucleotide as shown in Tables 3-10 a, b, 
c, d, e, and f. One pseudoelement (labeled c, u, a, g) corresponding to the terminal 
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nucleoside is also defined.  It does not matter which nucleoside is designated as the 
terminal group because we are only looking at the total base counts for successive 
fragments. The nucleotide compositions for each fragment were determined by using the 
monoisotopic mass to calculate the possible nucleotide compositions. Because the 
elemental composition constraints are limited to the four RNA nucleotides and the 
endgroup elements, only a small number of nucleotide compositions are calculated for 
even relatively large fragments within the error tolerance.  Without this constraint, it 
would be nearly impossible to determine a unique elemental composition (e.g. 
CvHwNxOyPz) for the larger fragments based on exact mass measurements alone.   
Candidate compositions were then ranked by matching the measured isotopic m/z 
values and relative abundances to the calculated values for each composition.  Candidate 
compositions for successive fragments that differed by more than a single nucleotide 
were rejected. The resulting nucleotide compositions were cross-checked against the 
expected compositions determined from the mass differences between the monoisotopic 
peaks for successive fragments. An example is shown in Table 3.11 for the 5’ ladder of 
miR-183.  Both “blind” samples (miR-183 and miR-124) were completely sequenced by 
this method with 100% accuracy. 
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Table 3.10. Isotopic composition of “pseudoelements” C,U,A,G and protonated U 
showing exact masses and relative abundances 
 
C (C9H12N3O7P) 
 
U (C9H11N2O8P) 
 
m/z Rel. abundance 
 
m/z Rel. abundance 
 
305.04129 100 
 
306.02531 100 
 
306.04408 11.247 
 
307.02829 10.904 
 
307.0459 2.016 
 
308.02997 2.184 
 
308.04843 0.179 
 
309.03266 0.195 
 
309.05042 0.017 
 
310.03455 0.021 
 
310.0528 0.001 
 
311.03705 0.002 
      
      
      
      
 
A (C10H12N5O6P) 
 
G (C10H12N5O7P) 
 
m/z Rel. abundance 
 
m/z Rel. abundance 
 
329.05252 100 
 
345.04744 100 
 
330.05503 13.029 
 
346.04995 13.067 
 
331.05703 2.02 
 
347.05193 2.23 
 
332.05935 0.189 
 
348.05426 0.217 
 
333.06145 0.017 
 
349.05634 0.021 
 
334.06367 0.001 
 
350.05857 0.002 
 
 
  
 
 
      
      
 
 
    
 
c (protonated cytidine C9H14N3O5) 
   
 
m/z Rel. abundance 
   
 
244.09335 100 
   
 
245.09613 11.194 
   
 
246.09804 1.599 
   
 
247.10052 0.132 
   
 
248.10262 0.01 
   
 
249.10494 0.001 
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Table 3.11. Nucleotide compositions calculated from miR-183 3’ fragments. 
Calc. m/z Abund % mmu ppm DBE Composition  Difference 
1490.237780 6.042 -11.34 -7.61 4.0 c1C1U2A1  
1796.263090 4.127 -3.57 -1.99 5.0 c1C1U3A1 (U)      
2125.315610 11.945 0.80 0.37 5.0 c1C1U3A2 (A)         
2454.368130 20.823 2.72 1.11 5.0 c1C1U3A3 (A)       
2799.415570 22.450 2.89 1.03 6.0 c1C1U3A3G1 (G)       
3128.468090 32.772 5.54 1.77 6.0 c1C1U3A4G1 (A)       
3434.493400 12.240 2.45 0.71 7.0 c1C1U4A4G1 (U)       
3779.540840 14.741 8.48 2.24 8.0 c1C1U4A4G2 (G)       
4124.588280 9.731 9.38 2.27 9.0 c1C1U4A4G3 (G)       
4430.613590 6.114 -3.24 -0.73 10.0 c1C1U5A4G3 (U)       
4735.654880 4.540 1.37 0.29 11.0 c1C2U5A4G3 (C)       
5064.707400 10.374 -4.27 -0.84 11.0 c1C2U5A5G3 (A) 
5369.748690 1.986 -4.55 -0.85 12.0 c1C3U5A5G3 (C)      
5714.796130 1.452 -19.27 -3.37 13.0 c1C3U5A5G4 (G)       
5714.758430 1.452 18.43 3.22 18.0 c1C5U5G7 *       
6059.843570 1.338 -20.33 -3.35 14.0 c1C3U5A5G5   (G)      
6059.805870 1.338 17.37 2.87 19.0 c1C5U5G8 *      
6365.868880 1.154 -2.67 -0.42 15.0 c1C3U6A5G5 (U) 
* Not a valid composition, out of sequence with the other compositions. 
DBE - Double bond equivalent, mmu – milli mass unit/ millidalton. 
 
 
Table 3.11 shows nucleotide compositions calculated from exact masses 
measured for monoisotopic peaks of fragment ions having relative abundances >3% in 
the Spiral TOF mass spectrum of miR-183 (pUAUGGCACUGGUAGAAUUCACU). 
The labels in parentheses show the nucleotide difference from the preceding composition. 
These differences reveal the partial sequence shown in bold.   
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To ensure the correct assignment of the nucleotides C and U, a third approach was 
proposed for determining the monoisotopic masses for fragments where the monoisotopic 
peak is weak, absent, or unresolved was also developed. This approach is analogous to 
the method proposed by Senko, Beu and McLafferty for proteins and peptides in which a 
hypothetical amino acid “averagine” was defined. An examination of all of the sequences 
for human RNA in the miRNA database (http://www.mirbase.org/cgi-
bin/mirna_summary.pl?org=hsa) showed a nearly equal nucleotide distribution 
corresponding to C (23.20%), U (26.78%), A (23.52%), and  G (26.50%). Based on these 
values, we define an average nucleotide “averageotide” having the composition 
C9.5001H11.7321N3.7325O7.0325P and an average molecular weight of 321.6983 Da. Using 
these values to determine the monoisotopic mass for a 24 kDa miRNA precursor (hsa-
mir-328 MI0000804, average mass 24225.4 Da), we obtain an estimated value of 24214.3 
Da, which differs from the calculated value of 24214.2 by only 0.1 Da, or 4 ppm. 
This approach was not used for the de novo sequencing of the unknown samples 
reported herein because the monoisotopic peaks for each fragment were observed. 
However, the “averageotide” concept is expected to be useful for larger fragments or 
spectra with insufficient resolving power or signal-to-noise ratio. Although we calculated 
an average nucleotide based upon human miRNA sequences, it may be noted that 
alternative values could be calculated for other RNA populations or for DNA. All spectra 
shown, both from the AB MALDI-TOF and the Spiral TOF were obtained in the positive 
ion mode.  
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3.50 Conclusions 
Using hydrolysis and high-resolution MALDI, complete sequence coverage with 
100% accuracy for de novo sequencing of miRNA samples was achieved.  The method 
described herein can be automated and does not require any additional reagents other 
than the conventional MALDI-MS reagents for RNA measurement. The developed assay 
opens a way for high-throughput and low-cost direct sequencing of miRNA with the 
potential to detect modifications in mature miRNA such as nucleotide addition or 
deletion, as well as enzymatic modification of miRNA nucleotides commonly referred to 
as RNA editing. 
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CHAPTER IV 
MicroRNA MultiTool; A SOFTWARE FOR THE IDENTIFICATION OF 
MODIFIED AND UNMODIFIED microRNA FROM MASS SPECTROMETRIC 
DATA 
 
Figure 4.1. Schematic abstract showing the use of bioinformatics in microRNA 
identification from mass spectrometric data.
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4.10 Introduction 
MicroRNA (miRNA)  are a class of short endogenous non-coding RNA, ~19-25 
nucleotides in length that play a crucial role in post-transcriptional gene regulation by 
either triggering degradation or preventing translation of the target messenger RNAs. 
With the recent discovery that miRNA can control over 60% of human gene expression, 
it is not surprising that the field of miRNA biology has quickly gained considerable 
interest within the last decade (Griffiths-Jones et al. 2006). MiRNA can regulate a variety 
of cellular processes (Lee and Dutta 2009), (Lu et al. 2008) and have been implicated in 
the initiation and progression of 160+ human diseases (Jiang et al. 2009). For this reason, 
miRNAs have been intensely studied for their potential use as disease biomarkers or 
therapeutic targets (Melo and Esteller 2011).  
Numerous methods have been developed for the identification and 
characterization of miRNAs. These methods include polymerase chain reaction, northern 
blots, microarrays and mass spectrometry (MS) among others. Recently, MS emerged as 
an important tool for the analysis of nucleic acids due to its accuracy, sensitivity, 
efficiency and ability to perform high throughput measurements, furthermore, the ability 
of MS to measure the intrinsic property of miRNA i.e. mass, gives it an added advantage 
in miRNA measurements over the alternative molecular biology techniques that rely on 
measurement of secondary signals. The availability of high throughput assays for analysis 
of miRNA have made MS a more appealing technique for miRNA measurements 
(Wambua et al. 2012). We recently demonstrated that MS can be used for the accurate 
detection and de novo sequencing of miRNA (Wambua et al. unpublished data presented 
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in chapter III). Matrix assisted laser desorption ionization (MALDI) results in the 
generation of spectra which are dominated by singly charged ions that are relatively easy 
to interpret is therefore the preferred choice for oligonucleotide analysis (Bahr et al. 
2009). 
Currently, there are more than 2,100 human miRNA reported in the literature 
(Griffiths-Jones et al. 2008). Several miRNAs can coexist within the same sample and 
therefore, parallel analysis of miRNA is unavoidable. Except in cases where only very 
few miRNAs are analyzed, or only a few mass spectra are involved, the mass 
spectrometric data generated from miRNA measurements can be complex and manual 
data processing is tedious and challenging (Oberacher and Pitterl 2009). Recent studies 
have also revealed that just like other forms of RNA, miRNA can undergo nucleotide 
modification which plays a key role in miRNA maturation and function (Iida et al. 2009). 
MiRNA nucleotide modifications are important since modified miRNA are known to 
target transcripts that are different than those targeted by non-modified miRNA 
(Burroughs et al. 2010). According to MODOMICS; a comprehensive database resource 
for RNA modifications, there are more than 100 distinct nucleotide modifications 
(Czerwoniec et al. 2009). Whereas current molecular biology techniques are unable to 
identify miRNA modifications, MS has been used for the characterization of different 
RNA post-transcriptional modifications including identification of type and exact 
position of the RNA modification (Nakayama et al. 2011), (Mengel-Jørgensen and 
Kirpekar 2002). The phenomenon of miRNA modification adds a layer of complexity to 
the miRNA data interpretation, further underlining the importance of developing methods 
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and appropriate software capable of identifying both modified and unmodified miRNA 
(Mizuguchi et al. 2011). 
With these challenges in mind, the spectral interpretation of mass spectrometric 
data can quickly turn out to be the bottleneck in miRNA analysis (Griffiths-Jones et al. 
2008). The success of MS as a tool for the analysis of miRNA will therefore strongly 
depend on the development of relevant computational software with the ability to 
properly interpret and analyze the large-scale, high-dimensional data that is generated 
from MS experiments (Chandramouli and Qian 2009). 
To address the challenges associated with MS data analysis of both post-
transcriptionally modified and unmodified miRNA, we present here the development of a 
user-interactive software, termed as MicroRNA MultiTool. MicroRNA MultiTool has a 
graphical user interface that allows the user to directly utilize mass spectral data in order 
to identify miRNA by sequence, name, mass, accession number and RNA modification if 
any. Since the mass of miRNA can be directly used for its identification, MicroRNA 
MultiTool eliminates the need of performing tandem mass spectrometry on a miRNA for 
the sole purpose of its identification. 
4.20 MicroRNA MultiTool Functionalities 
The human miRNA sequences were obtained from miRBase; a database which 
serves as a primary repository for published miRNAs (http://www.mirbase.org/) 
(Griffiths-Jones et al. 2006) while RNA modifications were from MODOMICS; 
a comprehensive database for RNA modification (http://modomics.genesilico.pl/) 
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(Czerwoniec et al. 2009). As shown in Figure 4.2, the MicroRNA MultiTool graphical 
user interface is divided primarily into three features as discussed in sections 4.21) 
miRNA search and mass calculator, 4.22) modified miRNA mass calculator and 4.23) 
miRNA fragment search. Help buttons are strategically placed with appropriate 
information to guide the user on the functions offered by the program. 
 
Figure 4.2. MicroRNA MultiTool graphical user interface. 
4.21 MiRNA search and mass calculator 
The graphical user interface for miRNA search and mass calculator function and 
its output are shown in Figure 4.3 (a) and (b) respectively. This purpose of this function is 
to match the data obtained from a mass spectrometric measurement to possible masses of 
all known human miRNA. This feature is especially important when miRNA are to be 
identified from mass spectral data with no other information available. In the interface 
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shown in Figure 4.3 (a) the “Mass in Daltons” field accepts numeric values and is 
provided for searching modified or unmodified miRNA. To search for the identity of a 
miRNA, a specific mass from MS data is entered into the Mass in Daltons field, in the 
“Options” panel the ionization mode used to acquire the MS data i.e. “Protonated” for 
positive ion mode or “Deprotonated” for negative ion mode is selected, mono isotopic or 
average mass and the type of 3’ and 5’ terminal groups on the miRNA can also be 
determined. On the “Options” panel, the option of “Use Modification” is provided to the 
user if they are searching for modified miRNA, with the default set at “No” under “Use 
Modifications” for searching unmodified miRNA. Clicking on Calculate returns the 
result of the analysis. The result of the search is a list of all unmodified miRNAs 
matching the entered mass together with their names, accession numbers, sequence and 
molecular masses as shown in Figure 4.3(b). 
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4.3 (a) 
 
 
 
4.3 (b) 
 
Figure 4.3. (a) Graphical user interface for miRNA search and mass calculator function 
and (b) its results output. 
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An especially unique function of the miRNA search and mass calculator feature 
compared to other RNA mass calculators is the ability to identify miRNA that may carry 
a modification on one of the nucleotides as well as the possible modification. This is done 
by first entering the mass as obtained from the mass spectrometric measurement in the 
“Mass in Daltons field” shown in Figure 4.3 (a), selecting desired options in the Options 
panel as explained in the previous section, followed by selecting “Yes” under “Use 
Modifications”, then “Calculate”. The software algorithm then scans each miRNA in the 
database and evaluates the sum of the miRNA mass plus the mass of any one of the 
known miRNA modification. This is done for all the known human miRNA and all RNA 
modifications. The output consists of the modified miRNA mass, name, accession 
number and modification as shown in Figure 4.4.  
 
Figure 4.4. Modified miRNA search results output. 
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Depending on the type of mass spectrometer used, the mass accuracy can vary 
greatly. In order to account for different accuracy levels of various mass spectrometers, 
the user is offered the option to define a +/- range in Daltons (Da) around the 
experimental mass which the program algorithm can use to search for matching miRNA 
masses. The defaults in the options panel are set at positive ionization mode, average 
mass, 5’ phosphate, 3’ hydroxyl, no modification and +/- 0.01 Da range. After all options 
have been made, the user clicks the “Calculate” button to return the results.  
The “Sequence”, “MIMAT” and “miR Name” fields of the miRNA search and 
mass calculator feature accepts RNA sequence (A,G,C,U), accession number and miRNA 
name entries respectively. If the entry matches any known miRNA, the program returns 
all parameters associated with the miRNA including its accession number, name, 
sequence and mass. The choices on the option panel can be selected as previously 
explained. Spaces entered between inputs are automatically ignored. An example with 
hsa-miR-153 entered in the name field is shown in Figure 4.5 (a) while the output is 
shown in Figure 4.5 (b). 
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4.5 (a) 
 
 
4.5 (b) 
 
Figure 4.5. (a) miRNA search and mass calculator user interface showing the various 
fields for data entry and (b) the output panel generated using miRNA name. 
 
116 
 
4.22 Modified miRNA mass calculator 
To provide pre-experimental miRNA sample analysis, MicroRNA MultiTool 
offers a novel feature whose purpose is to simulate expected mass data of modified 
miRNA. In Figure 4.6 (a) the data entry field provided in the Modified miRNA mass 
calculator interface accepts input in the form of miRNA name e.g. hsa-miR-153. A drop 
down menu with RNA modifications is provided from which the user can select a single 
modification. The program calculates the total mass of the miRNA and the modification 
and returns an output as shown in Figure 4.6 (b) consisting of the mass of the unmodified 
miRNA selected, mass of modified miRNA and the modification chosen. 
 
Figure 4.6. (a) MicroRNA MultiTool modified miRNA mass calculator user interface. 
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Figure 4.6. (b) MicroRNA MultiTool modified miRNA mass calculator user output. 
4.23 MiRNA fragment search 
The miRNA fragment search feature shown in Figure 4.7 (a) allows the alignment 
of RNA sequence of any length against all known human miRNA for a match. Once 
miRNA match(es) containing the queried sequence are found, MicroRNA MultiTool 
returns the matching miRNA name, accession number and sequence(s) of all miRNAs 
containing the input sequence fragment shown in Figure 4.7 (b).  
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4.7 (a) 
 
4.7 (b) 
 
Figure 4.7. (a) MiRNA fragment search feature and (b) its output panel. 
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4.30 Discussion 
The current strategy for identifying miRNA by MS relies on first obtaining the 
mass of the miRNA, followed by tandem mass spectrometry (MS/MS) in which the 
miRNA is fragmented through different ways such as collision induced dissociation 
(CID). The resulting fragment ions are then used to deduce a sequence that can be 
matched to possible miRNA identity (Izumi et al. 2011). Even though a few groups have 
recently reported the complete sequence assignment of RNA greater than 19 nucleotides 
long by MS/MS, this process does not always yield sufficient sequence coverage to 
enable miRNA identification (Taucher and Breuker 2010), (Taucher et al. 2010), (Huang 
et al. 2008). The determination of miRNA identity from MS data rather than MS/MS is 
therefore a simpler, straightforward and more appealing approach to this challenge, 
however, the bioinformatics tools necessary for the direct identification of miRNA from 
MS data are lacking. 
Currently, there are several bioinformatics tools available for assisting in the 
interpretation of MS data e.g. McCloskey’s group developed the Mongo Oligo Mass 
Calculator; a multipurpose program for the calculation of oligonucleotide molecular 
masses, CID fragments as well as endonuclease and exonuclease digestion fragments 
(Cantara et al. 2011). Simple Oligonucleotide Sequencer (SOS) from the same group is a 
useful tool for the determination of oligonucleotide sequences from CID MS/MS data 
(Rozenski and McCloskey 2002). The Compas program developed by Oberacher et al 
uses comparative sequencing of oligonucleotides for the sequence verification of nucleic 
acids by matching the predicted CID-MS/MS data with the multiply charged anionic 
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peaks obtained from an analyzed sample (Oberacher et al. 2004). These current programs 
have helped in the interpretation of MS data. However, none of these programs is capable 
of identifying miRNA from MS data. MicroRNA MultiTool offers a simple yet practical 
solution to this challenge by allowing the user to match molecular masses obtained in a 
MS experiment against molecular masses of all human miRNA in order to identify the 
measured miRNA. This approach of identifying miRNA directly from mass spectral data 
eliminates the need to perform MS/MS experiments for the sole purpose of miRNA 
identification. 
Due to the short nature of miRNAs, isobaric miRNAs i.e. miRNAs with different 
RNA sequences but identical molecular masses do exist. Under these circumstances, 
MicroRNA Multitool can be used to narrow down the identity of isobaric miRNA by 
returning a list of all the isobaric miRNA with the queried mass. For the absolute 
identification of isobaric miRNAs, currently existing methods of isolation and 
identification can be used. We have previously demonstrated that isobaric miRNA can be 
identified by capturing them using complementary probes followed by MS measurement. 
To help in the identification of miRNA when a partial sequence is available, MicroRNA 
MultiTool sequence alignment tool can be used. The algorithm searches for miRNA 
bearing queried partial sequence and matches it to known miRNA. Partial sequences of 
miR-153 were querried in MicroRNA Multitool and the results of matching number of 
miRNA tabulated in Table 4.1. From these results, it is clear that as low as 45.4 % 
sequence information can be used to positively identify hsa-miR-153 whose sequence is 
5' pUUGCAUAGUCACAAAAGUGAUC-OH 3'. This is because the partial sequence 
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[5’ pUUGCAUAGUC 3’] is unique to miR-153. MicroRNA MultiTool therefore 
provides an opportunity for incomplete sequencing data to be used for miRNA 
identification. 
Table 4.1. Alignment of hsa-miR-153 using MicroRNA MultiTool 
5' pUUGCAUAGUCACAAAAGUGAUC-OH 3'  (hsa-miR-153) 
Partial sequence No of miRNAs with partial Seq. % sequence coverage 
pUUGCAUAGUC 1 45.4 
pUUGCAUAGU 3 40.9 
pUUGCAUAG 3 36.3 
pUUGCAUA 5 31.8 
pUUGCAU 17 27.2 
pUUGCA 58 22.7 
pUUGC 174 18.1 
pUUG 597 13.6 
pUU 1101 9.0 
pU 1722 4.5 
 
 
The presence of post-transcriptionally modified nucleotides in various forms of 
RNA such as tRNA has been known for many decades. So far, there are more than 100 
known RNA modifications (Czerwoniec et al. 2009). The specific roles of most 
modifications still remains unknown; however, modifications are well conserved across 
evolution and are thought to be important for the general wellness of the organisms. Just 
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like other forms of RNA, miRNA are susceptible to different forms of post-
transcriptional enzymatic editing and covalent modifications (Jonatha et al. 2007). 
Nucleotide modifications are capable of altering the way in which miRNA interact with 
target mRNA molecules (Pantano et al. 2010). This can result to changes in gene 
regulation (Ebhardt et al. 2009) and the development of various diseases such as cancer 
(Galeano et al. 2011). Even though most of the RNA modifications are functionally and 
structurally important, the conventional and currently available molecular biology based 
techniques such as microarrays, qRT-PCR and northern blots or sequencing methods are 
incapable of detecting or identifying RNA modifications (Kellner et al. 2010). Except for 
the “mass silent” pseudouridylation modification which involves the isomerization of 
uridine to pseudouridine without any molecular mass changes (Taucher et al. 2011), most 
miRNA modifications result in mass shifts with respect to the unmodified miRNA. Since 
the mass shifts are characteristic of the modification, MS analysis is a useful tool for the 
identification of modified miRNA as well as the specific modification involved (Meng 
and Limbach 2006). For the identification of modified miRNA, the MicroRNA 
MultiTool algorithm uses a database of all known human miRNA together with known 
RNA modifications and computes all possible permutations for modified miRNA within 
the user queried mass. The return includes modified miRNA mass, name, accession 
number and modification involved. To accurately predict a modified miRNA, the 
program does not require the sequence, name or accession number of the miRNA, rather, 
the only input required is the mass of the modified miRNA as obtained from MS 
experiment. The mass is used to automatically generate a list of all modified miRNA 
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together with the modification(s) involved. Usually spectra generated from MALDI-MS 
are easier to analyze since they are mainly dominated by singly charged ions (Bahr et al. 
2009) this is also true when using MicroRNA MultiTool, however, in other cases where 
multiply charged ions are observed such as in electrospray ionization MS, the spectra 
should be deconvoluted prior to using the MicroRNA MultiTool. 
 
4.40 Conclusions 
This study was aimed at simplifying the identification of miRNA from mass 
spectrometric data. MicroRNA MultiTool provides the ability to search the identity of 
miRNA using a single parameter e.g. miRNA mass, sequence, accession number or name 
one at a time and return the other three related parameters. Given that miRNA therapeutic 
agents are already being explored as possible therapies for numerous diseased conditions, 
the rapid identification of miRNA will play a key role into the development of such 
therapies. The development of computational tools for the interpretation of MS data can 
greatly reduce the complexity associated with analysis of MS data while increasing the 
speed with which the data can be processed.  
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APPENDIX A 
MICRORNA MULTITOOL MAIN JAVA CLASS 
 
 
MicroRNA MultiTool Main Java Class is written in Java language and the code that 
determines the algorithm of the calculations is given below. 
1. package rna; 
 
2. import java.io.BufferedReader; 
3. import java.io.FileReader; 
4. import java.io.IOException; 
5. import java.text.DecimalFormat; 
6. import java.util.ArrayList; 
7. import java.util.Collections; 
8. import java.util.List; 
9. import java.util.Scanner; 
10. import java.awt.*; 
11. import javax.swing.*; 
12. import java.awt.event.*; 
13. import java.net.URL; 
 
14. /* This program was created by 
15. Norman H.L Chiu, Dickson M. Wambua and Zhonghao Cui 
16. For the use of calculating the masses of  
17. user-input RNA sequences and of calculating 
18. the masses of modified strands of RNA, 
19. in addition to predicting the presence of modified  
20. RNA sequences. 
21. *  
22. June 9th, 2011 
23. */ 
24. public class RNA { 
 
25. public static String RNAinput; 
26. public static double AdeMass = 329.2091; 
27. public static double CytMass = 305.1840; 
28. public static double UriMass = 306.1687; 
29. public static double GuaMass = 345.2084; 
30. public static double QueMass = 409.3998; 
31. public static double ThyMass = 304.1964; 
32. public static double OHmass = 17.0027; 
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33. public static double Phosmass = 95.9793; 
34. public static double positivenegative = 2.01565; 
35. public static double Acount; 
36. public static double Ccount; 
37. public static double Ucount; 
38. public static double Gcount; 
39. public static double Tcount; 
40. public static double Qcount; 
41. public static double five_end; 
42. public static double three_end; 
43. public static double TotalMass; 
44. public static String[] words; 
45. public static String[] microRNAs; 
46. public static double mass; 
47. public static boolean match = false; 
48. public static int wrong; 
 
49. public RNA() { 
50. // Default, with Avg mass, Positive Mode (Protonated), 5' Phos and 3' OH terms. 
51. AdeMass = 329.2091; 
52. CytMass = 305.1840; 
53. UriMass = 306.1687; 
54. GuaMass = 345.2084; 
55. positivenegative = 2.0157; 
56. } 
 
57. public RNA(boolean mono_iso, boolean pos_neg, boolean five_prime, boolean 
three_prime) { 
58. if (mono_iso) { 
59. AdeMass = 329.05252; 
60. CytMass = 305.04129; 
61. UriMass = 306.02530; 
62. GuaMass = 345.04744; 
63. QueMass = 409.15974; 
64. ThyMass = 304.04604; 
65. } else if (!mono_iso) { 
66. AdeMass = 329.2091; 
67. CytMass = 305.1840; 
68. UriMass = 306.1687; 
69. GuaMass = 345.2084; 
70. QueMass = 409.3998; 
71. ThyMass = 304.1964; 
72. } 
73. if (pos_neg) { 
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74. positivenegative = 2.01565; 
75. } else if (!pos_neg) { 
76. positivenegative = 0; 
77. } 
78. if (five_prime) { 
79. five_end = OHmass; 
80. } else if (!five_prime) { 
81. five_end = Phosmass; 
82. } 
83. if (three_prime) { 
84. three_end = OHmass; 
85. } else if (!three_prime) { 
86. three_end = Phosmass; 
87. } 
 
88. } 
 
89. // Gets an RNA sequence from the user: 
90. public static String getInput(String temp) { 
91. RNAinput = temp; 
92. for (int i = 0; i < RNAinput.length(); i++) { 
93. if (RNAinput.charAt(i) != 'A' && RNAinput.charAt(i) != 'C' 
94. && RNAinput.charAt(i) != 'U' && RNAinput.charAt(i) != 'G' && 
RNAinput.charAt(i) != 'Q') { 
95. System.out.println("This is not a valid RNA sequence."); 
96. } 
97. } 
98. return RNAinput; 
99. } 
 
100. public static boolean testInput(String temp) { 
101. boolean valid=true; 
102. temp = temp.toUpperCase(); 
103. temp = temp.replaceAll(" ", ""); 
104. RNAinput = temp; 
105. for (int i = 0; i < RNAinput.length(); i++) { 
106. if (RNAinput.charAt(i) != 'A' && RNAinput.charAt(i) != 'C' 
107. && RNAinput.charAt(i) != 'U' && RNAinput.charAt(i) != 'G' && 
RNAinput.charAt(i) != 'Q' && RNAinput.charAt(i) != 'T') { 
108. valid = false; 
109. } 
110. } 
111. return valid; 
112. } 
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113. // Accesses/imports a database of possible RNA modifications 
114. // for use in the program. 
115. public static String[] getModDBfromTextFile() { 
116. List<String> wordList = new ArrayList<String>(); 
117. BufferedReader br = null; 
118. try { 
119. br = new BufferedReader(new FileReader("ModDB.txt")); 
120. String word; 
121. while ((word = br.readLine()) != null) { 
122. wordList.add(word); 
123. } 
124. } catch (IOException e) { 
125. e.printStackTrace(); 
126. } finally { 
127. try { 
128. br.close(); 
129. } catch (IOException ex) { 
130. ex.printStackTrace(); 
131. } 
132. } 
133. String[] temp = new String[wordList.size()]; 
134. words = temp; 
135. wordList.toArray(words); 
 
136. return words; 
137. } 
 
138. // Accesses/imports a database of all mature homo sapien miRNA 
139. // sequences. 
140. public static String[] getRNADBfromTextFile() { 
141. List<String> wordList = new ArrayList<String>(); 
142. BufferedReader br = null; 
143. try { 
144. br = new BufferedReader(new FileReader("miRDB.txt")); 
145. String RNAword; 
146. while ((RNAword = br.readLine()) != null) { 
147. wordList.add(RNAword); 
148. } 
149. } catch (IOException e) { 
150. e.printStackTrace(); 
151. } finally { 
152. try { 
153. br.close(); 
144 
 
154. } catch (IOException ex) { 
155. ex.printStackTrace(); 
156. } 
157. } 
158. String[] temp = new String[wordList.size()]; 
159. microRNAs = temp; 
160. wordList.toArray(microRNAs); 
161. return microRNAs; 
162. } 
 
163. // Counts number of Adenines in the user-input RNA sequence. 
164. public static double countAdenine() { 
165. for (int i = 0; i < RNAinput.length(); i++) { 
166. if (RNAinput.charAt(i) == 'A') { 
167. Acount++; 
168. } 
169. } 
170. return Acount; 
171. } 
 
172. // Counts number of Cytosine in the user-input RNA sequence. 
173. public static double countCytosine() { 
174. for (int i = 0; i < RNAinput.length(); i++) { 
175. if (RNAinput.charAt(i) == 'C') { 
176. Ccount++; 
177. } 
178. } 
179. return Ccount; 
180. } 
 
181. // Counts number of Uridine in the user-input RNA sequence. 
182. public static double countUridine() { 
183. for (int i = 0; i < RNAinput.length(); i++) { 
184. if (RNAinput.charAt(i) == 'U') { 
185. Ucount++; 
186. } 
187. } 
188. return Ucount; 
189. } 
 
190. // Counts number of Guanine in the user-input RNA sequence. 
191. public static double countGuanine() { 
192. for (int i = 0; i < RNAinput.length(); i++) { 
193. if (RNAinput.charAt(i) == 'G') { 
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194. Gcount++; 
195. } 
196. } 
197. return Gcount; 
198. } 
 
199. // Counts number of Thymidine in the user-input RNA sequence. 
200. public static double countThymidine() { 
201. for (int i = 0; i < RNAinput.length(); i++) { 
202. if (RNAinput.charAt(i) == 'T') { 
203. Tcount++; 
204. } 
205. } 
206. return Tcount; 
207. } 
 
208. // Counts number of Queuosines in the user-inout RNA sequence. 
209. public static double countQueuosine() { 
210. for (int i = 0; i < RNAinput.length(); i++) { 
211. if (RNAinput.charAt(i) == 'Q') { 
212. Qcount++; 
213. } 
214. } 
215. return Qcount; 
216. } 
 
217. // Returns the mass of RNA sequence. 
218. public static double calcTotalMass(String temp) { 
219. getInput(temp); 
220. Acount = 0; 
221. Gcount = 0; 
222. Ccount = 0; 
223. Ucount = 0; 
224. Qcount = 0; 
225. Tcount = 0; 
226. countAdenine(); 
227. countCytosine(); 
228. countGuanine(); 
229. countUridine(); 
230. countQueuosine(); 
231. countThymidine(); 
232. TotalMass = (Acount * AdeMass) + (Ccount * CytMass) 
233. + (Ucount * UriMass) + (Gcount * GuaMass) + (Tcount * ThyMass) + (Qcount * 
QueMass) - Phosmass + five_end + three_end + positivenegative; 
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234. String TotalMassString = Double.toString(TotalMass); 
235. int decimal = TotalMassString.indexOf("."); 
236. TotalMassString = TotalMassString.substring(0,decimal+6);  
237. TotalMass = Double.parseDouble(TotalMassString); 
238. return TotalMass; 
239. } 
 
240. public static String getHsaName(String sequence) { 
241. String[] rnadb = getRNADBfromTextFile(); 
242. for (int i = 1; i < rnadb.length; i += 2) { 
243. if (rnadb[i].equals(sequence)) { 
244. int hsaEnd = rnadb[i-1].indexOf(" "); 
245. return rnadb[i - 1].substring(0,hsaEnd); 
246. } 
247. } 
248. return ""; 
249. } 
 
250. public static String getHsaMimat(String mimat){ 
251. String[] rnadb = getRNADBfromTextFile(); 
252. for (int i = 0; i < rnadb.length; i += 2) { 
253. int hsaEnd = rnadb[i].indexOf(" "); 
254. if (rnadb[i].substring(hsaEnd+1,rnadb[i].length()).equals(mimat)) { 
255. return rnadb[i].substring(0,hsaEnd); 
256. } 
257. } 
258. return ""; 
259. } 
 
260. public static String getMimat(String sequence){ 
261. String[] rnadb = getRNADBfromTextFile(); 
262. for (int i = 1; i < rnadb.length; i += 2) { 
263. int hsaEnd = rnadb[i-1].indexOf(" "); 
264. if (rnadb[i].equals(sequence)) { 
265. return rnadb[i - 1].substring(hsaEnd+1, rnadb[i-1].length()); 
266. } 
267. } 
268. return ""; 
269. } 
 
270. public static String getSequence(String miRname) { 
271. String[] rnadb = getRNADBfromTextFile(); 
272. for (int i = 0; i < rnadb.length; i += 2) { 
273. int hsaEnd = rnadb[i].indexOf(" "); 
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274. if (rnadb[i].substring(0,hsaEnd).equals(miRname)) { 
275. return rnadb[i + 1];                 
276. } 
277. } 
278. return ""; 
279. } 
 
280. // Method that returns miRNA sequences with similar weights to 
281. // the one input. 
282. public static String getPossibleRNA(double testMass, double Range) { 
283. ArrayList<String> RNAmatches = null; 
284. StringBuffer sb = new StringBuffer(); 
285. String testString = Double.toString(testMass); 
286. RNAmatches = new ArrayList<String>(); 
287. getRNADBfromTextFile(); 
288. for (int i = 1; i < microRNAs.length - 1; i += 2) { 
289. double datmass = calcTotalMass(microRNAs[i]); 
290. String dataMass = Double.toString(datmass); 
291. int decimal = dataMass.indexOf("."); 
292. dataMass = dataMass.substring(0,decimal+6); 
293. String RNAmass = new String(microRNAs[i - 1] + ", " + microRNAs[i] 
294. + ", " + dataMass) 
295. + " Da"; 
296. Double dbmass = calcTotalMass(microRNAs[i]); 
297. if (dbmass >= testMass - Range && dbmass <= testMass + Range) { 
298. RNAmatches.add(RNAmass); 
299. } 
300. } 
301. for (String s : RNAmatches) { 
302. sb.append(s + "\n"); 
303. } 
304. String matches = sb.toString(); 
305. return matches; 
306. } 
 
307. // Finds the input modification in the database and retrieves 
308. // the mass of the modification. 
309. public static double getMassofMod(String mod) { 
310. getModDBfromTextFile(); 
311. for (int i = 0; i < words.length; i++) { 
312. if (words[i].equals(mod)) { 
313. if (mod.length() <= 4) { 
314. String sr = words[i + 2]; 
315. mass = Double.parseDouble(sr); 
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316. return mass; 
317. } else { 
318. String sr = words[i + 1]; 
319. mass = Double.parseDouble(sr); 
320. return mass; 
321. } 
322. } 
323. } 
324. System.out.println("The modification you entered is invalid."); 
325. return -1; 
326. } 
 
327. // Method that returns new mass of a RNA string after modifications 
328. // have been made. 
329. public static double findNewModMass(String temp, char einin, double modimass) 
{ 
330. temp = temp.toUpperCase(); 
331. getInput(temp); 
332. countAdenine(); 
333. countCytosine(); 
334. countUridine(); 
335. countGuanine(); 
336. countQueuosine(); 
337. if (einin == 'A' && Acount!=0) { 
338. double newMass = ((Acount - 1) * AdeMass) + (Ccount * CytMass) 
339. + (Ucount * UriMass) + (Gcount * GuaMass) + (Qcount * QueMass) + modimass 
340. Phosmass + five_end + three_end + positivenegative; 
341. return newMass; 
342. }  
343. else if (einin == 'A' && Acount==0){ 
344. return calcTotalMass(temp); 
345. } 
346. else if (einin == 'C' && Ccount!=0) { 
347. double newMass = (Acount * AdeMass) + ((Ccount - 1) * CytMass) 
348. + (Ucount * UriMass) + (Gcount * GuaMass) + (Qcount * QueMass) + modimass 
349. Phosmass + five_end + three_end + positivenegative; 
350. return newMass; 
351. }  
352. else if (einin == 'C' && Ccount==0){ 
353. return calcTotalMass(temp); 
354. } 
355. else if (einin == 'U' && Ucount!=0) { 
356. double newMass = (Acount * AdeMass) + (Ccount * CytMass) 
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357. + ((Ucount - 1) * UriMass) + (Gcount * GuaMass) + (Qcount * QueMass) + 
modimass 
358. Phosmass + five_end + three_end + positivenegative; 
359. return newMass; 
360. }  
361. else if (einin == 'U' && Ucount==0){ 
362. return calcTotalMass(temp); 
363. } 
364. else if (einin == 'G' && Gcount!=0) { 
365. double newMass = (Acount * AdeMass) + (Ccount * CytMass) 
366. + (Ucount * UriMass) + ((Gcount - 1) * GuaMass )+ (Qcount * QueMass) + 
modimass 
367. Phosmass + five_end + three_end + positivenegative; 
368. return newMass; 
369. } 
370. else if (einin == 'G' && Gcount==0){ 
371. return calcTotalMass(temp); 
372. } 
373. if (einin == 'Q' && Qcount!=0) { 
374. double newMass = (Acount * AdeMass) + (Ccount * CytMass) 
375. + (Ucount * UriMass) + (Gcount * GuaMass) + ((Qcount-1) * QueMass) + 
modimass 
376. Phosmass + five_end + three_end + positivenegative; 
377. return newMass; 
378. }  
379. return -1; 
380. } 
 
381. // Method that returns new mass of a RNA string after modifications 
382. // have been made. 
383. public static double apply_new_mod(double startMass, char einin, double 
modmass, String startString) { 
384. double finalMass = 0; 
385. Acount = 0; 
386. Ucount = 0; 
387. Gcount = 0; 
388. Ccount = 0; 
389. Qcount = 0; 
390. startString.toUpperCase(); 
391. getInput(startString); 
392. countAdenine(); 
393. countGuanine(); 
394. countCytosine(); 
395. countUridine(); 
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396. countQueuosine(); 
397. if (einin == 'A' && Acount != 0) { 
398. finalMass = startMass - AdeMass + modmass; 
399. } 
400. if (einin == 'A' && Acount == 0){ 
401. finalMass = startMass; 
402. } 
403. if (einin == 'C' && Ccount != 0) { 
404. finalMass = startMass - CytMass + modmass; 
405. } 
406. if (einin == 'C' && Ccount == 0){ 
407. finalMass = startMass; 
408. } 
409. if (einin == 'G' && Gcount != 0) { 
410. finalMass = startMass - GuaMass + modmass; 
411. } 
412. if (einin == 'G' && Gcount == 0){ 
413. finalMass = startMass; 
414. } 
415. if (einin == 'U' && Ucount != 0) { 
416. finalMass = startMass - UriMass + modmass; 
417. } 
418. if (einin == 'U' && Ucount == 0){ 
419. finalMass = startMass; 
420. } 
421. if (einin == 'Q' && Qcount != 0) { 
422. finalMass = startMass - QueMass + modmass; 
423. } 
424. if (einin == 'Q' && Qcount == 0){ 
425. finalMass = startMass; 
426. } 
427. return finalMass; 
428. } 
 
429. // Method that, when given a sequence of RNA, returns all the weights 
430. // of that RNA with one modification. All of the modifications 
431. // in the database are used. 
432. public static ArrayList<String> allModdedMasses(String hsamir) { 
433. ArrayList<String> massList = null; 
434. massList = new ArrayList<String>(); 
435. String rnaseq = null; 
436. getModDBfromTextFile(); 
437. getRNADBfromTextFile(); 
438. for (int i = 0; i < microRNAs.length; i += 2) { 
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439. if (hsamir.equals(microRNAs[i])) { 
440. rnaseq = microRNAs[i + 1]; 
441. break; 
442. } 
443. } 
444. for (int i = 3; i < words.length; i += 4) { 
445. double mass = 0; 
446. Acount = 0; 
447. Gcount = 0; 
448. Ccount = 0; 
449. Ucount = 0; 
450. String modificationmass = words[i]; 
451. int decimal = modificationmass.indexOf("."); 
452. modificationmass = modificationmass.substring(0,decimal+6); 
453. Double modmass = Double.parseDouble(modificationmass); 
454. String temp = words[i - 2]; 
455. String modname = words[i - 1]; 
456. int space = temp.indexOf(' '); 
457. char nucleotide = temp.charAt(space + 1); 
458. mass = findNewModMass(rnaseq, nucleotide, modmass);      
459. String massString = Double.toString(mass); 
460. String printString = new String(massString + ": " + hsamir + " with " + 
modname); 
461. massList.add(printString); 
462. } 
463. return massList; 
464. } 
 
465. public static String findMatchingRNA(String s, double Range) { 
466. String inputString = null; 
467. StringBuffer strbuff = new StringBuffer(); 
468. ArrayList<String> possibles = null; 
469. possibles = new ArrayList<String>(); 
470. getModDBfromTextFile(); 
471. getRNADBfromTextFile(); 
472. double inputMass = 0; 
473. if (s.charAt(0) == '1' 
474. || s.charAt(0) == '2' 
475. || s.charAt(0) == '3' 
476. || s.charAt(0) == '4' 
477. || s.charAt(0) == '5' 
478. || s.charAt(0) == '6' 
479. || s.charAt(0) == '7' 
480. || s.charAt(0) == '8' 
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481. || s.charAt(0) == '9' 
482. || s.charAt(0) == '0') { 
483. inputMass = Double.parseDouble(s); 
484. } else if (s.substring(0, 3).equals("hsa")) { 
485. for (int i = 0; i < microRNAs.length; i += 2) { 
486. if (s.equals(microRNAs[i])) { 
487. inputString = microRNAs[i + 1]; 
488. break; 
489. } 
490. } 
491. inputMass = calcTotalMass(inputString); 
492. } else if (s.charAt(0) == 'A' || s.charAt(0) == 'C' || s.charAt(0) == 'G' || s.charAt(0) 
== 'U') { 
493. inputString = s; 
494. inputMass = calcTotalMass(inputString); 
495. } 
496. if (inputMass == 0) { 
497. System.err.println("Input Invalid! Please try again with valid input."); 
498. return ""; 
499. } 
500. for (int i = 1; i < microRNAs.length; i += 2) { 
501. double DBmass = calcTotalMass(microRNAs[i]); 
502. if ((inputMass - Range) <= DBmass && DBmass <= (inputMass + Range)) { 
503. possibles.add(DBmass + ": " + microRNAs[i - 1]); 
504. } 
505. } 
506. ArrayList<String> oneModList = null; 
507. oneModList = new ArrayList<String>(); 
508. for (int c = 0; c < microRNAs.length; c += 2) { 
509. oneModList.addAll(allModdedMasses(microRNAs[c])); 
510. } 
511. ArrayList<String> twoModList = null; 
512. twoModList = new ArrayList<String>(); 
513. for (String st : oneModList) { 
514. int index = st.indexOf(':'); 
515. String weightstring = st.substring(0, index); 
516. int decimal = weightstring.indexOf("."); 
517. weightstring = weightstring.substring(0,decimal+6);  
518. Double onemodWeight = Double.parseDouble(weightstring); 
519. if ((inputMass - Range) <= onemodWeight && onemodWeight <= (inputMass + 
Range)) { 
520. possibles.add(st); 
521. } 
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522. // 2 Modifications 
523. twoModList.clear(); 
524. int secIndex = st.indexOf("with"); 
525. String miR_oneMod = st.substring(index); 
526. // NOTE: The weight of the one-modded miRNA is above in onemodWeight. 
527. // NOTE: Sequence is rna_seq 
528. // NOTE: Nucleotide to be modified is nucleo 
529. // NOTE: Mass of mod is mod_mass 
530. // NOTE: miR_oneMod = [Mass]: [hsa-mir] with [mod] 
531. String hsa = st.substring(index + 2, secIndex - 1); 
532. String rna_seq = null; 
533. for (int b = 0; b < microRNAs.length; b += 2) { 
534. if (hsa.equals(microRNAs[b])) { 
535. rna_seq = microRNAs[b + 1]; 
536. break; 
537. } 
538. } 
539. String oneListModname = st.substring(secIndex + 5); 
540. int strt_snd_mod = 0; 
541. for (int v = 2; v < words.length; v += 4) { 
542. if (oneListModname.equals(words[v])) { 
543. strt_snd_mod = v; 
544. break; 
545. } 
546. } 
547. strt_snd_mod += 1; 
548. for (int g = strt_snd_mod; g < words.length; g += 4) { 
549. String modif_mass = words[g]; 
550. double mod_mass = Double.parseDouble(modif_mass); 
551. String nomenc = words[g - 2]; 
552. String mod_name = words[g - 1]; 
553. char nucleo = nomenc.charAt(nomenc.indexOf(' ') + 1); 
554. double finalMass = apply_new_mod(onemodWeight, nucleo, mod_mass, 
rna_seq); 
555. String massString = Double.toString(finalMass); 
556. decimal = massString.indexOf("."); 
557. massString = massString.substring(0,decimal+6);  
558. twoModList.add(massString + miR_oneMod + " and " + mod_name); 
559. } 
560. for (String ts : twoModList) { 
561. int colon_index = ts.indexOf(':'); 
562. String two_mass_string = ts.substring(0, colon_index); 
563. decimal = two_mass_string.indexOf("."); 
564. two_mass_string = two_mass_string.substring(0,decimal+6);  
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565. Double two_mass_double = Double.parseDouble(two_mass_string); 
566. if ((inputMass - Range) <= two_mass_double && two_mass_double <= 
(inputMass + Range)) { 
567. possibles.add(ts); 
568. } 
569. } 
570. System.out.println(possibles.size()); 
571. } 
572. System.out.println("there are: " + possibles.size() + " results"); 
573. System.out.println("the range is +/- " + Range); 
574. System.out.println("the input mass was: " + inputMass); 
575. for (String o : possibles) { 
576. strbuff.append(o + "\n"); 
577. } 
578. String matches = strbuff.toString(); 
579. return matches; 
580. } 
 
581. // Method if the database-retrieved RNA is any number of spaces longer than 
582. // the input RNA. testRNA is the RNA given by the user to the system to find 
583. // similar RNAs. 
584. // DBRNA will be the various RNAs in the entire miR database. 
585. public static boolean findMatch(String testRNA, String DBRNA) { 
586. StringBuffer strbuff = new 
StringBuffer().append("00").append(DBRNA).append("00"); 
587. String newDBRNA = strbuff.toString(); 
588. int wrong; 
589. int diff = Math.abs(newDBRNA.length() - testRNA.length()); 
590. boolean matchMore = false; 
591. for (int i = 0; i < diff + 1; i++) { 
592. wrong = 0; 
593. for (int j = 0; j < testRNA.length(); j++) { 
594. if (!(testRNA.charAt(j) == newDBRNA.charAt(i + j))) { 
595. wrong++; 
596. } 
597. if (wrong > 0) { 
598. break; 
599. } 
600. if ((j == testRNA.length() - 1) && (wrong <= 0)) { 
601. matchMore = true; 
602. System.out.println(matchMore); 
603. return matchMore; 
604. } 
605. } 
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606. } 
607. System.out.println(matchMore); 
608. return matchMore; 
609. } 
 
610. // This method determines whether each of the 1733 elements in the database 
611. // match, and if they do, 
612. // it adds the miRNA sequence to an ArrayList of matches. 
613. public String getSimilar(String rna) { 
614. ArrayList<String> matchList = null; 
615. StringBuffer sb = new StringBuffer(); 
616. matchList = new ArrayList<String>(); 
617. Scanner sc = new Scanner(System.in); 
618. String[] datbase = getRNADBfromTextFile(); 
619. for (int i = 1; i < datbase.length; i += 2) { 
620. if (datbase[i].length() > rna.length()) { 
621. boolean ifmatch = findMatch(rna, datbase[i]); 
622. if (ifmatch) { 
623. matchList.add(datbase[i - 1] + ", " + datbase[i]); 
624. } 
625. } else if (datbase[i].length() > rna.length() - 3 
626. && datbase[i].length() < rna.length()) { 
627. boolean ifmatch = findMatch(datbase[i], rna); 
628. if (ifmatch) { 
629. matchList.add(datbase[i - 1] + ", " + datbase[i]); 
630. } 
631. } else if (datbase[i].length() == rna.length()) { 
632. boolean ifmatch = findMatch(rna, datbase[i]); 
633. if (ifmatch) { 
634. matchList.add(datbase[i - 1] + ", " + datbase[i]); 
635. } 
636. } 
637. } 
638. for (String s : matchList) { 
639. sb.append(s + "\n"); 
640. } 
641. String matches = sb.toString(); 
642. System.out.println(sb.toString()); 
643. return matches; 
644. } 
645. } 
